Imaging a target fluorophore in a biological material in the presence of autofluorescence

Information

  • Patent Grant
  • 10488340
  • Patent Number
    10,488,340
  • Date Filed
    Tuesday, October 31, 2017
    6 years ago
  • Date Issued
    Tuesday, November 26, 2019
    4 years ago
Abstract
Methods and systems are disclosed for extracting an image of a target fluorophore in a biological material, which involve inducing both autofluorescence of the biological material and fluorescence of the fluorophore, acquiring an image arising from both the autofluorescence of the biological material and the fluorophore, and an image arising only from the autofluorescence, subtracting the two images to produce an image representing only the fluorophore, wherein relative intensities of the excitation light used to induce the autofluorescence and the fluorescence are modulated prior to acquiring the images.
Description
TECHNICAL FIELD

The present invention relates generally to fluorescence imaging, and in particular to imaging a target fluorophore in a biological material in the presence of autofluorescence.


BACKGROUND

In the life sciences, fluorescence is typically used as a non-invasive method of identifying and analyzing biological materials. Specific targets in the biological material such as for example, proteins, nucleic acids, lipids, cells and cell components, stem cells or small molecules can be labeled with an extrinsic or exogenous fluorophore, and thus subsequently imaged. Biological materials also naturally fluoresce, which is known as intrinsic fluorescence or “autofluorescence” because it occurs in the absence of exogenously administered fluorophores. Autofluorescence is believed to originate from various endogenous fluorophores in biological materials, including for example nicotinamide adenine dinucleotide (NADH), elastin, collagen, flavins, amino acids and porphyrins.


Autofluorescence and fluorescence emission can be generated and recorded as images when light with the appropriate excitation wavelengths illuminates the biological material. However, autofluorescence, which is the result of a combination of fluorophores and is characterized by broad emission spectra extending over several hundred nanometers, can interfere with the ability to detect the emission of a specific fluorophore, when the emission spectra of the fluorophore and the autofluorescence overlap. In such instances, in addition to reducing signal detection sensitivity by masking the fluorescence of the fluorophore of interest, autofluorescence may also decrease the specificity of detection by providing false positive results.


One approach to addressing this problem is to utilize means to reduce or minimize the detected emission signal that is contributed by autofluorescence of the biological material. The prior art describes methods to reduce autofluorescence by employing various pre-treatments of the biological material prior to image acquisition. However, such techniques may also degrade the quality of the biological material itself, and are typically not suitable for in vivo applications. Alternatively, if the autofluorescence emission itself cannot be mitigated, it is possible to minimize the contribution of signal from autofluorescence to image data by means of digital manipulation of any acquired fluorescence images. For example, in images containing the combined signal from both the fluorophore of interest and autofluorescence, some of these methods rely on acquiring estimates of the “pure” autofluorescence signal and using such estimates to remove autofluorescence by a weighted subtraction. Other methods use statistical correlation techniques to correct for the additive autofluorescence signal. These image data manipulation techniques are described in prior art references and are generally limited by poor accuracy, by the need for small (i.e., low resolution) data sets, or by the need for significant post-processing. It is consequently desirable to establish a high resolution image processing technique to quickly and accurately distinguish the fluorescence emitted by a fluorophore of interest in a biological material from the autofluorescence emission in that same biological material.


SUMMARY

In accordance with one aspect of the invention, there is provided a method for extracting an image of a target fluorophore in a biological material wherein a waveband for the target fluorophore emission overlaps a waveband for autofluorescence emission in the biological material. The method includes illuminating the biological material with a first excitation light to induce a first fluorescence emission arising from both autofluorescence of the biological material and fluorescence of the target fluorophore and with a second excitation light to induce a second fluorescence emission arising from the autofluorescence of the biological material, acquiring a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission, and processing the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore, wherein relative intensities of the first and second excitation lights are modulated prior to acquiring the first and second fluorescence images. The processing may for example involve subtracting the second fluorescence image from the first fluorescence image.


According to an embodiment, the modulation of the relative intensities includes identifying a wavelength region in the first and second fluorescence emissions, wherein the wavelength region is a region where emission arising from the fluorophore is present in the first fluorescence emission and absent in the second fluorescence emission, selecting a waveband outside the wavelength region, calculating at the selected waveband a ratio of relative intensities of the first and second fluorescence emissions, and adjusting the relative intensities of the first and second excitation lights to adjust the corresponding first fluorescence emission, second fluorescence emission or both until a suitable calculated ratio is achieved. According to an embodiment, the ratio of relative intensities of the first and second fluorescence emissions may be calculated by dividing an area-under-the curve value corresponding to the first fluorescence emission by an area-under-the curve value corresponding to the second fluorescence emission.


In accordance with another aspect of the invention, there is provided a system for extracting an image of a target fluorophore in a biological material wherein a waveband for the target fluorophore emission overlaps a waveband for autofluorescence emission in the biological material. The system includes a light source configured to illuminate the biological material with a first excitation light to induce a first fluorescence emission arising from both autofluorescence of the biological material and fluorescence of the target fluorophore and with a second excitation light to induce a second fluorescence emission arising from the autofluorescence of the biological material, an image acquisition assembly configured to acquire a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission, a modulator configured to modulate relative intensities of the first and second excitation lights prior to acquisition of the first and second fluorescence images, and a processor assembly configured to process the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore. According to an embodiment, the light source configured to illuminate the biological material includes an illumination module, the image acquisition assembly includes a fluorescence emission acquisition module, and the processor assembly includes a processor module.


In the embodiments where the target fluorophore is porphyrin, for example, the first excitation light has a wavelength of about 405 nm, the second excitation light has a wavelength of about 450 nm, the selected waveband is about 600 nm, and the calculated ratio is about 1.





BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.


In accompanying drawings which illustrate embodiments of the invention,



FIG. 1 schematically illustrates an exemplary method according to an embodiment;



FIGS. 2A-2C illustrates fluorescence spectra arising from autofluorescence and porphyrin in urine (FIG. 2A), autofluorescence (FIG. 2B) in urine, and the differential spectrum corresponding to porphyrin alone obtained in accordance with the various embodiments (FIG. 2C);



FIGS. 3A-3B illustrates fluorescence spectra of freshly obtained urine (3A) and photobleached urine (3B) at 405 nm and 450 nm according to an embodiment;



FIGS. 4A-4F illustrates images corresponding to the fluorescence spectra in FIGS. 3A-3B where the left column (FIGS. 4A, 4C, 4E) relates to freshly collected urine, and the right column (FIGS. 4B, 4D, 4F) relates to photobleached urine, the top row (FIGS. 4A, 4B) relates to fluorescence images from excitation at about 405 nm, the middle row (FIGS. 4C, 4D) relates to fluorescence images from excitation at about 450 nm, and the bottom row (FIGS. 4E, 4F) illustrates the differential images corresponding to the target fluorophore (porphyrin) obtained according to an embodiment;



FIG. 5A illustrates an example in vivo fluorescence image of the subject's forearm when excited with 405 nm light, displaying autofluorescence from the forearm and porphyrin fluorescence; FIG. 5B illustrates a fluorescence image of the same region of the forearm as in FIG. 5A upon excitation with 450 nm light showing a reduction in autofluorescence to a level similar to the autofluorescence level in FIG. 5A where the porphyrin fluorescence is absent under the 450 nm excitation; FIG. 5C illustrates a fluorescence image of porphyrin with the autofluorescence removed in accordance with an embodiment;



FIG. 6A illustrates background intensity values at 405 nm and 450 nm after the excitation intensities were adjusted at 600 nm, and a lower than about 2% difference between background values was observed between excitations; FIG. 6B illustrates a comparison of the signal-to-noise ratio from fluorescence images excited at 405 nm and after background was removed in accordance with an embodiment;



FIG. 7 illustrates a system for extracting an image of a target fluorophore in a biological material according to an embodiment;



FIG. 8 illustrates an illumination module according to an embodiment; and



FIG. 9 illustrates a fluorescence emission acquisition module according to an embodiment.





DETAILED DESCRIPTION

Reference will now be made in detail to implementations and embodiments of various aspects and variations of the invention, examples of which are illustrated in the accompanying drawings.


According to one aspect of the invention, there is provided a method for extracting an image of a target fluorophore in a biological material wherein a waveband for the target fluorophore emission overlaps a waveband for autofluorescence emission in the biological material. FIG. 1 schematically illustrates the method of the present invention according to an embodiment. Referring to FIG. 1, the method comprises illuminating the biological material with a first excitation light to induce a first fluorescence emission arising from both autofluorescence of the biological material and fluorescence of the target fluorophore and with a second excitation light to induce a second fluorescence emission arising from the autofluorescence of the biological material, acquiring a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission, and processing the first and second fluorescence images to obtain a third fluorescence image representing the target fluorophore, wherein relative intensities of the first and second excitation lights are modulated prior to acquiring the first and second fluorescence images.


In various embodiments, the biological material includes a material derived from, obtained from, or located in a biological subject (e.g., a mammal), and further includes a material in vitro, in situ or in vivo. Examples of the biological material include a biological tissue or fluid or a fraction thereof, an organ, a cell, a cell line, a cell constituent derived from or located in mammals including humans. The biological material includes a collection of cells obtained from, derived from or in a tissue of the subject such as, for example, epithelium, connective tissue, blood vessels, muscle, nerve tissue, bone from any time in development of the subject. In various embodiments, the biological material includes healthy, diseased, or malignant tissue (e.g., cancerous or tumour tissue) comprising the target fluorophore (e.g., porphyrin). An example of the biological material further includes bacteria, including bacteria present in the subject (human, animal). Examples of the biological material which is a fluid include urine, serum, blood plasma, or blood. In various embodiments, the biological material may be a tissue section used in histochemistry, immunohistochemistry, cytochemistry, immunofluorescence, immunoblotting or other fluorescence-related imaging applications.


In various embodiments, the target fluorophore in the biological material is a fluorophore which when excited by a particular wavelength of light emits a light at a different, typically longer, wavelength. The target fluorophore includes a fluorophore which is of analytical, prognostic, diagnostic, physiological, pathological interest or a combination thereof. In various embodiments, the target fluorophore may be naturally occurring in the biological material (i.e., an endogenous fluorophore), externally administered into the biological material (i.e., an exogenous fluorophore) in a precursor or final form, or a combination thereof. Examples of naturally occurring or endogenous fluorophores include porphyrins, nicotinamide adenine dinucleotide (NAD), elastin, collagen, flavins, and amino acids. In embodiments where a porphyrin is the target fluorophore, the porphyrin includes a class of organic compounds that are in relevant biological systems and are formed as precursor intermediates in the biosynthesis of heme. For example, in humans and other mammals, porphyrins with 8-, 7-, 6-, 5- and 4-carboxyl groups are commonly formed in excess for heme synthesis, and thus are excreted in urine. In various embodiments, the term “porphyrin” includes, for example, porphyrin derivatives, coproporphyrin, uroporphyrin, protoporphyrin, porphyrin conjugates, liposomes, and nanovesicles.


Examples of exogenous fluorophores include various fluorescent probes or fluorescence inducing agents which may be used to augment (e.g., enhance) or provide fluorescent properties to a component of the biological material. For example, a fluorescent probe may associate with or attach to the component of the biological material to, for example, enhance fluorescence of an endogenous fluorophore in the component. Examples of exogenous fluorescent probes include fluorescein isothiocyanate (FITC), fluorescein, a fluorescent dye, 4′,6-diaminidino-2-phenylindole (DAPI), and eosin. An example of a fluorescence inducing agent includes a gene which may be inserted into a cell chromosome to induce the production of fluorescent proteins (e.g., green fluorescent protein). The fluorescence inducing agent may be an adjuvant that can augment the fluorescence response of the target fluorophore. For example, in embodiments where the target fluorophore is porphyrin, the adjuvant may be a selected food source (e.g., porphyrinogenic foods or chemicals), aminolevulinic acid or inhibitors of certain enzymes in the HEME pathway (e.g., ferrochelatease inhibitors) which when consumed or administered to the subject, increase the fluorescence response of porphyrin.


The biological material naturally fluoresces or “autofluoresces” in the absence of exogenously administered fluorophores due to the presence of various endogenous fluorophores in the biological material. Autofluorescence originates from various fluorophores in the biological material, including for example nicotinamide adenine dinucleotide (NAD), elastin, collagen, flavins, amino acids, lipofuscins, advanced glycation end-products, and porphyrins. The biological material includes a material that has been processed or otherwise treated prior to being used in the various embodiments of the method and system of the invention. For example, in certain embodiments, pre-treatment may involve photobleaching of the biological material to reduce the autofluorescence of the biological material presumably by inactivating some of the autofluorescent endogenous fluorophores, and thus facilitating clearer subsequent resolution of the target fluorophore in cases where the target fluorophore is comparatively less susceptible to photobleaching or photobleaches at a slower rate than autofluorescent fluorophores in the biological material.


In accordance with the various embodiments, the method comprises illuminating the biological material with a first excitation light to induce a first fluorescence emission arising from both autofluorescence of the biological material and fluorescence of the target fluorophore, and with a second excitation light to induce a second fluorescence emission arising from the autofluorescence of the biological material. In various embodiments, the wavelength of the first excitation light is selected such that when the first excitation light illuminates the biological material, the fluorophores in the biological material which give rise to autofluorescence and the target fluorophore are both excited and emit a first fluorescence emission. In various embodiments, the wavelength of the second excitation light is selected such that only the fluorophores in the biological material giving rise to autofluorescence are excited and emit a second fluorescence emission. In various embodiments, for example, the first excitation light may have a wavelength ranging from about 350 nm to about 450 nm and the second excitation light may have a wavelength ranging from about 450 nm to about 700 nm. Illumination of the biological material with the first excitation light and the second excitation light includes intermittent illumination, continuous illumination or a combination thereof.


In the embodiment where the target fluorophore is porphyrin, the first excitation light has a wavelength of about 405 nm, and the second excitation light has a wavelength of about 450 nm. FIGS. 2A-2C (shaded areas) illustrates data obtained from porphyrin in urine. In particular, FIG. 2A is a first fluorescence emission spectrum arising from both autofluorescence and porphyrin in urine, and FIG. 2B is a second fluorescence emission spectrum arising from autofluorescence only. FIG. 2C is the differential spectrum corresponding to porphyrin only. In the examples illustrated in FIGS. 2A-2C, the urine was pretreated by photobleaching to facilitate a better discrimination of porphyrin from autofluorescence. In particular, photobleaching pre-treatment was conducted by illuminating the urine with the second excitation light of a wavelength of about 450 nm for about 3 minutes, which resulted in improved discrimination of the phorphyrin from autofluorescence of urine as compared with untreated urine (FIGS. 3A-3B). FIGS. 3A-3B shows fluorescence spectra from freshly obtained urine (FIG. 3A) and spectra obtained following an approximately 3-minute photobleaching exposure of the urine to light at about 450 nm (FIG. 3B).


In accordance with the various embodiments, the method comprises acquiring a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission, and processing the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore wherein the relative intensities of the first and second excitation light are modulated prior to acquiring the first and second fluorescence images. FIGS. 4A to 4D are images corresponding to the spectra in FIGS. 3A-3B acquired when the urine is freshly obtained and when the urine has been exposed to light at about 450 nm for about 3 minutes. FIGS. 4E and 4F are the differential images corresponding to porphyrin only resulting from the processing as described in connection with the various embodiments.


According to an embodiment, modulation of the relative intensities prior to image acquisition comprises identifying a wavelength region in the first and second fluorescence emissions, wherein the wavelength region is a region where emission arising from the fluorophore is present in the first fluorescence emission and absent in the second fluorescence emission, selecting a waveband outside the wavelength region, calculating at the selected waveband a ratio of relative intensities of the first and second fluorescence emissions, and adjusting the relative intensities of the first and second excitation lights to adjust the corresponding first fluorescence emission, second fluorescence emission or both until a suitable calculated ratio is achieved. According to various embodiments a waveband includes a wavelength. For example, in the embodiments where the target fluorophore is porphyrin, as is shown in FIG. 2C or FIG. 3B, the wavelength region where the emission arising from porphyrin is present in the first fluorescence emission and absent in the second fluorescence emission ranges, for example, from about 615 nm to about 625 nm and from about 660 nm to about 700 nm. Therefore, 600 nm was selected as the waveband outside this wavelength region and used as the waveband at which the ratio of the relative intensities at 405 nm and 450 nm was calculated for determining whether adjustment of the relative intensities is needed. In this example, the relative intensities were adjusted until the calculated ratio of about 1 was achieved within +/−2%. In this example, the ratio was calculated at the 600 nm waveband by dividing an area-under-the curve value corresponding to the first fluorescence emission (i.e., the emission arising from excitation at about 405 nm) by an area-under-the curve value corresponding to the second fluorescence emission (i.e., the emission arising from excitation at about 450 nm). In various embodiments, the ratio may be calculated by dividing the intensity at the selected waveband (e.g., a selected wavelength) of the first fluorescence emission by the intensity at the selected waveband (e.g., a selected wavelength) of the second fluorescence emission. In various embodiments, other methods may be used for calculation of the ratio. For example, one or more intensity points in the spectra arising from the respective emissions at 405 nm and 450 nm at the selected waveband (e.g., 600 nm) rather than areas may be used for such a calculation.


In various embodiments, processing comprises subtracting the second fluorescence image from the first fluorescence image to produce an autofluorescence-free image of the target fluorophore (e.g., FIGS. 4E and 4F).


The methods and systems according to the various embodiments may be used for detecting in situ fluorescence. Experimental data in FIGS. 5A-5C and 6A-6B illustrate example results where porphyrin was applied topically on the skin of a subject. In this example, a porphyrin solution was prepared by dissolving about 0.1 mg of coproporphyrin ester (Sigma-Aldrich) in about 10 mL of dimethyl sulfoxide (DMSO, Sigma Aldrich). The porphyrin solution was applied onto a small area of the subject's forearm using a Q-tip. The fluorescence imaging system used to acquire the data featured a dual-excitation capability at the porphyrin absorption maxima of about 405 nm and about 450 nm. The latter was chosen as the shortest wavelength outside the main porphyrin absorption band, and due to its property to induce high levels of tissue autofluorescence. To ensure that the reflected excitation light does not interfere with the fluorescence images, a 600 nm band pass filter (600 nm±5 nm) was placed in front of the detector in the imaging system, and the excitation intensities at 405 nm and 450 nm were modulated until the ratio of autofluorescence at 450 nm to autofluorescence at 405 nm reached about 1. FIG. 5A is an in vivo fluorescence image of the subject's forearm when excited with 405 nm light displaying autofluorescence from the forearm and porphyrin fluorescence. FIG. 5B is a fluorescence image of the same region of the forearm as in FIG. 5A upon excitation with 450 nm light. Since the autofluorescence induced by 450 nm excitation is greater than the autofluorescence induced by 405 nm excitation, the excitation light at 450 nm was modulated to produce autofluorescence at a level similar to the autofluorescence level in FIG. 5A. FIG. 5C illustrates a fluorescence image of porphyrin with the autofluorescence removed in accordance with an embodiment.



FIG. 5A illustrates that the use of single excitation at 405 nm produces a well-localized fluorescence region arising from porphyrin fluorescence. High levels of background in surrounding areas arise from the presence of several endogenous fluorophores in skin (e.g., flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide (NAD) and lipids). A similar autofluorescence pattern can also be observed when the same region was excited with different excitation wavelength (450 nm) away from the absorption spectra of porphyrins (FIG. 5B). FIG. 5C shows the resultant image after the processing according to the methods of the present invention where the autofluorescence was successfully attenuated using the method.



FIG. 6A illustrates background intensity values at 405 nm and 450 nm after the excitation intensities were adjusted at 600 nm, and a lower than about 2% difference between background values was observed between excitations. FIG. 6B illustrates a comparison of the signal-to-noise ratio (S/N Ratio) from fluorescence images excited at 405 nm and after background was removed in accordance with an embodiment. An increase in the S/N Ratio can be achieved using this approach as compared to using single excitation at 405 nm (see FIG. 6B where S/N Ratios of about 28.5 and about 1.9, respectively, are shown).


Various conventional approaches involve simultaneous acquisition of the fluorescence images where all fluorescence species are illuminated, and their fluorescence emissions are collected at the same time. The acquired images are then processed using one or more autofluorescence removal models involving spectral unmixing or background subtraction. Although various conventional approaches have been proposed for removing autofluorescence such, as for example, spectral unmixing (linear decomposition) and digital background subtraction to reveal the differential, such approaches rely on manipulating the images post-acquisition and pre-characterized spectra for autofluorescence, require calibration, and are susceptible to changes in sensitivity based on the concentration of the target fluorophore. While these methods may be cost effective and applicable to both in vitro and in vivo imaging, they are not able to completely remove the autofluorescence component from fluorescence images, and further to account for an instrumental background signal. The modulation of relative intensities of the first and second excitation lights prior to image acquisition, as described in connection with the various embodiments, compensates for relative changes in emission with time due to, for example, different rates of photobleaching between the target fluorophore (e.g., porphyrin) and the fluorophores in the biological material giving rise to autofluorescence. If the modulation of intensities is performed digitally post-image acquisition, as is described in the prior art, the accuracy of the processing of the two images to derive the image of the target fluorophore (e.g., subtraction) is decreased, especially if the magnitude of the first and second fluorescence signals is significantly different. Prior art spectral unmixing methods often require prior knowledge of the amount of autofluorescence in the sample, which may not be constant. In addition, images of the biological material may also include a certain amount of noise or background contributed by the acquisition system itself. Therefore, in contrast to the present invention, normalization of intensities post-image acquisition, as taught in the prior art, is noisier and limited in signal quality especially when the target fluorophore has a low level signal as compared to the autofluorescence signal (e.g., endogenous fluorophores or fluorophores in low-concentration components of the biological material). Furthermore, post-image acquisition amplification of the low level signal of the target fluorophore, as taught in the prior art, also amplifies the instrumental background signal, which further negatively impacts the signal quality. Unlike the prior art approaches, the present invention facilitates dynamic real-time correction for changes in fluorescence in the biological material, and therefore enables a real time representation of the nature of the biological material.


The data generated according to the various embodiments demonstrates that the dual-excitation method of the present invention, as described in connection with the various embodiments, facilitates a reduction in or mitigates the fluorescence background signal during fluorescence imaging of biological tissue by modulating the autofluorescence intensities at a selected wavelength prior to acquisition of fluorescence images. According to the various embodiments, acquisition of spectral images is carried out by timed excitation and light collection from only a target fluorophore of interest or background at a time. This temporal separation of excitation and fluorescence collection minimizes cross-talk. Instead of collecting the emission signal under the same excitation source, the present method according to the various embodiments, induces equivalent background levels by means of a second excitation wavelength (which does not induce fluorescence from the target fluorophore of interest), and then can be subsequently subtracted without decreasing the fluorescence signal from the target fluorophore of interest.


The present method can be beneficial for fluorescence imaging applications where tissue autofluorescence affects fluorescence imaging. The detection of equivalent autofluorescence signatures from different excitation sources facilitates a more accurate molecular diagnosis than a single fluorescence excitation. Moreover, the dual fluorescence imaging approach in accordance with the various embodiments is more robust and accurate than other post-processing analysis techniques since the fluorescence intensity of the fluorophore of interest is not affected by digitally removing the background or modulating the background levels. As is illustrated by the experimental data collected according to an embodiment, this method may be used for the identification of malignant tissues in vivo by exploiting the preferential accumulation of fluorophores such as porphyrins.


In accordance with an aspect of the invention, there is provided a system for extracting an image of a target fluorophore in a biological material. The system comprises a light source configured to illuminate the biological material with a first excitation light to induce a first fluorescence emission arising from both autofluorescence of the biological material and fluorescence of the target fluorophore and with a second excitation light to induce a second fluorescence emission arising from the autofluorescence of the biological material, an image acquisition assembly configured to acquire first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission, a modulator configured to modulate relative intensities of the first and second excitation lights prior to acquisition of the first and second fluorescence images, and a processor assembly configured to process the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore.


Selected aspects relating to the system have been described above in connection with the various embodiments of the method of the present invention. Referring to FIG. 7, there is shown an exemplary embodiment of a system 10 for extracting the image of the target fluorophore 15 in the biological material 14. The system 10 comprises the means for illuminating 12 for illumination (e.g., a light source configured to illuminate the biological material) of the biological material 14 with dual fluorescence excitation light, means for acquiring 16 fluorescence images (e.g., an image acquisition assembly configured to acquire fluorescence images) arising from both the autofluorescence and the target fluorophore and from the autofluorescence alone, and means for processing 18 the acquired fluorescence images (e.g., a processor assembly configured to process the acquired images) to extract an image representing only the target fluorophore. In various embodiments, the means for illuminating 12 (e.g., the light source configured to illuminate the biological material) comprises, for example, an illumination module 20 shown in FIG. 8. The illumination module 20 comprises a fluorescence excitation source 22 operatively configured for providing fluorescence excitation having suitable intensities and suitable wavelengths for exciting the target fluorophore and the fluorophores giving rise to autofluorescence. In one embodiment, the fluorescence excitation source 22 may be a single excitation source having dual excitation capabilities for providing a first excitation light for inducing emission arising from both autofluorescence and fluorescence of the target fluorophore, and the second excitation light for inducing emission arising from the autofluoresence only. In another embodiment, the fluorescence excitation source 22 may comprise two excitation sources (not shown), one for providing the first excitation light and the other for providing the second excitation light. In various embodiments, the fluorescence excitation source 22 includes, for example, a laser diode (which may comprise, for example, one or more fiber-coupled diode lasers), one or more LEDs, arc lamps, or other illuminant technologies of sufficient intensity and appropriate wavelength for providing the first and second excitation lights. In various embodiments, the first and second excitation light from the fluorescence excitation source 22 may be projected through an optical element (i.e., one or more optical elements) to shape and guide the output being used to illuminate the biological sample. The shaping optical element may consist, for example, of one or more lenses, light guides and diffusers. As is illustrated in FIG. 8, the output 24 from the fluorescence excitation source 22 is passed through one or more focusing lenses 26, and then through a homogenizing light pipe 28 such as, for example, light pipes commonly available from Newport Corporation, USA. Finally, the light is passed through an optical diffuser 30 (i.e., one or more optical diffusers or diffractive elements) such as, for example, ground glass diffusers also available from Newport Corporation, USA. Power to the fluorescence excitation source 22 itself is provided by, for example, a high-current laser driver such as those available from Lumina Power Inc., USA. In the embodiment where the fluorescence excitation source 22 is a laser, the laser may be operated in a pulsed mode during the image acquisition process. In this embodiment, an optical sensor such as a solid state photodiode 32 is incorporated into the illumination module 20 and samples the illumination intensity produced by the illumination module 20 via scattered or defuse reflections from the various optical elements.


In an alternative embodiment, the means for illuminating 12 (e.g., the light source) may also be configured to provide an additional functionality such as white light illumination. In another embodiment, the method and system of the present invention may further comprise acquiring and combining the third fluorescence image representing the target fluorophore with a white light image of the biological material. In this manner, the location of the targeted fluorophore can be visualized within the context of the biological material. This is useful in instances in which the biological material cannot be viewed directly with the human eye.


In various embodiments, the illumination module 20 in FIG. 8 comprises means for modulating (not shown) the relative intensities of the first and second excitation lights from the fluorescence excitation source 22 (e.g., a modulator configured to modulate the relative intensities of the first and second excitation lights from the fluorescence excitation source), so as to allow intensity adjustment. Such modulation may include modulation of the power to the light source, mechanical interruption of the light beam by shutters, apertures or choppers, optical, opto-mechanical or electro-optical diversion, filtering or blocking of the light beam or similar modulation.


Referring back to FIG. 7, the means for acquiring 16 (e.g., an image acquisition assembly) comprises, for example, a fluorescence emission acquisition module 30 (e.g., a camera module) shown in FIG. 9 for acquiring the first and second fluorescence images. As is shown in FIG. 9, the fluorescence emission 42 from the target fluorophore in the biological material and the fluorescence emission from other fluorophores giving rise to autofluorescence or both is collected and focused onto an image sensor 44 using an arrangement of various optical elements, e.g., 46a, 46b, 48 and 50. The charge that results from the optical signal transduced by the image sensor 44 is converted to a video signal by the appropriate read-out and amplification electronics in the fluorescence emission acquisition module 30.


Referring back to FIG. 7, in various embodiments, the means for processing 18 (e.g., a processor assembly) comprises, for example, a processor module (not shown) for analyzing the emission signals, performing calculations for subtracting the second fluorescence image from the first fluorescence image to output the calculated information to an appropriate display and/or recording device. In various embodiments, the processor module comprises any computer or computing means such as, for example, a tablet, laptop, desktop or networked computer. In various embodiments, the processor module may have a data storage module with the capability to save data (e.g., image sequences) to a tangible non-transitory computer readable medium such as, for example, internal memory, a hard disk, or flash memory, so as to enable recording and/or post-processing of acquired data. In various embodiments, the processor module may have an internal clock to enable control of the various elements and ensure correct timing of illumination and sensor shutters. In various other embodiments, the processor module may also provide user input and graphical display of outputs. The imaging system may optionally be configured with a video display (not shown) to display the images as they are being acquired or played back after recording, or further to visualize the data generated at various stages of the method. In various embodiments, the means for processing (e.g., the processor assembly) is in communication with an imaging system or is a component of the imaging system. An example of the imaging system in accordance with an embodiment is an endoscope.


In operation, and with continuing reference to the embodiments in FIGS. 7 to 9, the biological material is positioned in the illumination path of the means for illuminating 12 (e.g., the light source) of the system 10 comprising the illumination module 20, and such that, for example, the illumination module 20 produces a substantially uniform field of illumination across substantially the entire area of the biological material. The fluorescence excitation source 22 (e.g., the laser diode) is turned on and begins the shutter sequence for the image sensor (e.g., image sensor 44 of the fluorescence emission acquisition module 30). The fluorescence emission from the biological material is collected by the front imaging optics of the fluorescence emission acquisition module 30 such as optics 46a for example in FIG. 9 at the selected waveband (e.g., for porphyrin the selected wavelength is about 600 nm), and a ratio of the relative intensities is calculated. If the calculated ratio is suitable (e.g., for porphyrin, a suitable calculated ratio is in the range of about 0.98 to 1.02), the first and second fluorescence images are acquired. If the ratio is not suitable, the relative intensities of the first and second excitation lights are modulated and re-calculated until the suitable ration is achieved. The obtained first and second fluorescence images are then subtracted to extract a third fluorescence image representing only the target fluorophore.


According to another aspect of the invention, there is provided a tangible non-transitory computer readable medium having computer-executable (readable) program code embedded thereon comprising a method for extracting an image of a target fluorophore in a biological material wherein a waveband for the target fluorophore emission overlaps a waveband for autofluorescence emission in the biological material, the method comprising:

    • illuminating the biological material with a first excitation light to induce a first fluorescence emission arising from both autofluorescence of the biological material and fluorescence of the target fluorophore and with a second excitation light to induce a second fluorescence emission arising from the autofluorescence of the biological material;
    • acquiring a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission; and
    • processing the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore, wherein relative intensities of the first and second excitation lights are modulated prior to acquiring the first and second fluorescence images.


One skilled in the art will appreciate that program code according to the various embodiments can be written in any appropriate programming language and delivered to the processor in many forms, including, for example, but not limited to information permanently stored on non-writeable storage media (e.g., read-only memory devices such as ROMs or CD-ROM disks), information alterably stored on writeable storage media (e.g., hard drives), information conveyed to the processor through communication media, such as a local area network, a public network such as the Internet, or any type of media suitable for storing electronic instruction. When carrying computer readable instructions that implement the various embodiments of the method of the present invention, such computer readable media represent examples of various embodiments of the present invention. In various embodiments, the tangible non-transitory computer readable medium comprises all computer-readable media, and the present invention scope is limited to computer readable media wherein the media is both tangible and non-transitory.


In yet further aspects, there is provided a kit including the system and the exogenous fluorophore as described in connection with the various embodiments.


Therefore, the various embodiments of the invention facilitate discrimination of the fluorescence of interest from an unknown combination of autofluorescence and fluorescence of interest. The present invention facilitates improvements in image quality for target fluorophores, preserves signal fluorescence while eliminating autofluorescence as well as background, and increases the resulting signal to autofluorescence ratio and the overall sensitivity of detection. The present invention is adaptable to a wide array of biological materials, and may be applied to any fluorescence imaging application. The present invention may be used to image and analyze a biological sample to discern the presence, absence, concentration, and/or spatial distribution of one of more fluorophore targets in the biological material. The present invention may be further used as a complementary tool for medical assessment or biological assessment (e.g., assessment of a biological phenomenon), diagnostic assessment, therapeutic assessment, physiological assessment, or a combination thereof.


While the present invention has been illustrated and described in connection with various embodiments shown and described in detail, it is not intended to be limited to the details shown, since various modifications and structural changes may be made without departing in any way from the scope of the present invention. Various modifications of form, arrangement of components, steps, details and order of operations of the embodiments illustrated, as well as other embodiments of the invention may be made without departing in any way from the scope of the present invention, and will be apparent to a person of skill in the art upon reference to this description. It is therefore contemplated that the appended claims will cover such modifications and embodiments as they fall within the true scope of the invention. For the terms “for example” and “such as,” and grammatical equivalences thereof, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.

Claims
  • 1. A method for extracting an image of a target fluorophore in a biological material wherein a waveband for emission of the target fluorophore overlaps a waveband for emission of a second fluorophore in the biological material, the method comprising: illuminating the biological material with a first excitation light to induce a first fluorescence emission arising from both fluorescence of the target fluorophore and fluorescence of the second fluorophore and with a second excitation light to induce a second fluorescence emission arising from only the fluorescence of the second fluorophore;acquiring a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission; andprocessing the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore, wherein relative intensities of the first and second excitation lights are modulated prior to acquiring the first and second fluorescence images.
  • 2. The method of claim 1, wherein the modulation of the relative intensities comprises: identifying a wavelength region in the first and second fluorescence emissions, wherein the wavelength region is a region where emission arising from the fluorophore is present in the first fluorescence emission and absent in the second fluorescence emission;selecting a waveband outside the wavelength region;calculating at the selected waveband a ratio of relative intensities of the first and second fluorescence emissions; andadjusting the relative intensities of the first and second excitation lights to adjust the corresponding first fluorescence emission, second fluorescence emission or both until a suitable calculated ratio is achieved.
  • 3. The method of claim 2, wherein the waveband outside the wavelength region comprises one or more wavelengths in fluorescence spectra arising from the first and second fluorescence emissions.
  • 4. The method of claim 2, wherein calculating the ratio of relative intensities of the first and second fluorescence emissions comprises dividing an area-under-the curve value corresponding to the first fluorescence emission by an area-under-the curve value corresponding to the second fluorescence emission.
  • 5. The method of claim 1, wherein the first excitation light has a wavelength of about 405 nm and the second excitation light has a wavelength of about 450 nm when the target fluorophore is porphyrin.
  • 6. The method of claim 2, wherein the selected waveband is about 600 nm and wherein the calculated ratio is about 1.
  • 7. The method of claim 1, wherein processing the first and second fluorescence images to extract the third fluorescence image representing the target fluorophore comprises subtracting the second fluorescence image from the first fluorescence image.
  • 8. The method of claim 1, wherein the biological material is pretreated by photobleaching.
  • 9. The method of claim 1, wherein the target fluorophore is endogenous, exogenous, or a combination thereof.
  • 10. The method of claim 9, wherein the endogenous fluorophore is porphyrin, a porphyrin precursor, a porphyrin analog, a porphyrin derivative, a porphyrin conjugate, a porphyrin liposome, a porphyrin nanovesicle, or a combination thereof.
  • 11. The method of claim 10, wherein the porphyrin comprises a coproporphyrin, a uroporphyrin, a protoporphyrin, or a combination thereof.
  • 12. The method of claim 11, wherein the exogenous fluorophore is a fluorescent dye, a fluorescence inducing agent, or a combination thereof.
  • 13. Use of the method of claim 1 in hystochemistry, cytochemistry, or a combination thereof.
  • 14. The method of claim 1, wherein the biological material comprises a biological tissue, a biological fluid, or a fraction thereof.
  • 15. The method of claim 1, wherein the biological material comprises an organ, a cell, a cell line, a cell constituent derived from or located in a mammal.
  • 16. The method of claim 1, wherein the biological material comprises healthy, diseased or malignant tissue.
  • 17. The method of claim 1, wherein the biological material comprises a tissue section for use in histochemistry, immunohistochemistry, cytochemistry, immunofluorescence, immunoblotting, or a fluorescence-related imaging application.
  • 18. The method of claim 1, comprising displaying images representing the target fluorophore as images from the first fluorescence emission and images of the second fluorescence emission are acquired.
  • 19. A system for extracting an image of a target fluorophore in a biological material wherein a waveband for emission of the target fluorophore overlaps a waveband for emission of a second fluorophore in the biological material, the system comprising: a light source configured to illuminate the biological material with a first excitation light to induce a first fluorescence emission arising from both fluorescence of the target fluorophore and fluorescence of the second fluorophore and with a second excitation light to induce a second fluorescence emission arising from only the fluorescence of the second fluorophore;an image acquisition assembly configured to acquire a first fluorescence image from the first fluorescence emission and a second fluorescence image from the second fluorescence emission;a modulator configured to modulate relative intensities of the first and second excitation lights prior to acquisition of the first and second fluorescence images; anda processor assembly configured to process the first and second fluorescence images to extract a third fluorescence image representing the target fluorophore.
  • 20. The system of claim 19, wherein the modulator is configured to: identify a wavelength region in the first and second fluorescence emissions, wherein the wavelength region is a region where emission arising from the fluorophore is present in the first fluorescence emission and absent in the second fluorescence emission;select a waveband outside the wavelength region;calculate at the selected waveband a ratio of relative intensities of the first and second fluorescence emissions; andadjust the relative intensities of the first and second excitation lights to adjust the corresponding first fluorescence emission, second fluorescence emission or both until a suitable calculated ratio is achieved.
  • 21. The system of claim 20, wherein the waveband outside the wavelength region comprises one or more wavelengths in fluorescence spectra arising from the first and second fluorescence emissions.
  • 22. The system of claim 20, wherein calculating the ratio of relative intensities of the first and second fluorescence emissions comprises dividing an area-under-the curve value corresponding to the first fluorescence emission by an area-under-the curve value corresponding to the second fluorescence emission.
  • 23. The system of claim 19, wherein the first excitation light has a wavelength of about 405 nm and the second excitation light has a wavelength of about 450 nm when the target fluorophore is porphyrin.
  • 24. The system of claim 20, wherein the selected waveband is about 600 nm and wherein the calculated ratio is about 1.
  • 25. The system of claim 19, wherein the processor assembly configured to process the first and second fluorescence images to extract the third fluorescence image representing the target fluorophore is configured for subtracting the second fluorescence image from the first fluorescence image.
  • 26. The system of claim 19, wherein the light source configured to illuminate the biological material comprises an illumination module comprising a fluorescence excitation source, the fluorescence excitation source operatively configured to generate the first and second excitation lights.
  • 27. The system of claim 26, wherein the illumination module further comprises an optical element operatively configured to shape and guide the first and second excitation lights exiting the illumination module.
  • 28. The system of claim 27, wherein the optical element comprises a lens, a light guide, a diffuser, or a combination thereof.
  • 29. The system of claim 19, wherein the image acquisition assembly comprises a fluorescence emission acquisition module, the fluorescence emission acquisition module comprising an image sensor.
  • 30. The system of claim 29, wherein the fluorescence emission acquisition module further comprises an optical element disposed in front of the image sensor operatively configured to capture, filter, and direct the first and second fluorescence emissions.
  • 31. The system of claim 19, wherein the processor assembly comprises a processor module.
  • 32. The system of claim 31, wherein the processor module is operatively configured to control an operation of the light source, to control an operation of the image acquisition assembly, or a combination thereof.
  • 33. The system of claim 19, wherein the biological material is pretreated by photobleaching.
  • 34. The system of claim 19, wherein the target fluorophore is endogenous, exogenous, or a combination thereof.
  • 35. The system of claim 34, wherein the endogenous fluorophore is porphyrin, a porphyrin precursor, a porphyrin analog, a porphyrin derivative, a porphyrin conjugate, a porphyrin liposome, a porphyrin nanovesicle, or a combination thereof.
  • 36. The system of claim 35, wherein the porphyrin comprises a coproporphyrin, a uroporphyrin, a protoporphyrin, or a combination thereof.
  • 37. The system of claim 34, wherein the exogenous fluorophore is a fluorescent dye, a fluorescence inducing agent, or a combination thereof.
  • 38. The system of claim 19, wherein the system is configured for displaying images representing the target fluorophore on a display as images from the first fluorescence emission and images of the second fluorescence emission are acquired.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 14/868,369, filed on Sep. 28, 2015, which claims benefit of U.S. Provisional Application No. 62/056,830, filed on Sep. 29, 2014, the disclosures of which are incorporated herein by reference in their entirety.

US Referenced Citations (327)
Number Name Date Kind
4109647 Stern et al. Aug 1978 A
4162405 Chance et al. Jul 1979 A
4200801 Schuresko Apr 1980 A
4263916 Brooks et al. Apr 1981 A
4394199 Barnhard, IV et al. Jul 1983 A
4473841 Murakoshi et al. Sep 1984 A
4532918 Wheeler Aug 1985 A
4541438 Parker et al. Sep 1985 A
4556057 Hiruma et al. Dec 1985 A
4619249 Landry Oct 1986 A
4718417 Kittrell et al. Jan 1988 A
4719508 Sasaki et al. Jan 1988 A
4768513 Suzuki Sep 1988 A
4773097 Suzaki et al. Sep 1988 A
4774568 Matsuo Sep 1988 A
4786813 Svanberg et al. Nov 1988 A
4805597 Iwakoshi Feb 1989 A
4815848 Hadeishi Mar 1989 A
4821117 Sekiguchi Apr 1989 A
4827908 Matsuo May 1989 A
4852579 Gilstad et al. Aug 1989 A
4858001 Milbank et al. Aug 1989 A
4860731 Matsuura Aug 1989 A
4867137 Takahashi Sep 1989 A
4868647 Uehara et al. Sep 1989 A
4900934 Peeters et al. Feb 1990 A
4930516 Alfano et al. Jun 1990 A
4938205 Nudelman Jun 1990 A
4957114 Zeng et al. Sep 1990 A
4993404 Lane Feb 1991 A
4995396 Inaba et al. Feb 1991 A
4995398 Turnidge Feb 1991 A
4998972 Chin et al. Mar 1991 A
5003977 Suzuki et al. Apr 1991 A
5042494 Alfano Aug 1991 A
5071417 Sinofsky Dec 1991 A
5078150 Hara et al. Jan 1992 A
5090400 Saito Feb 1992 A
5091652 Mathies et al. Feb 1992 A
5115137 Andersson-Engels et al. May 1992 A
5117466 Buican et al. May 1992 A
5125404 Kittrell et al. Jun 1992 A
5131398 Alfano et al. Jul 1992 A
5134662 Bacus et al. Jul 1992 A
5150292 Hoffmann et al. Sep 1992 A
5165079 Schulz-Hennig Nov 1992 A
5178616 Uemiya et al. Jan 1993 A
5196928 Karasawa et al. Mar 1993 A
5214503 Chiu et al. May 1993 A
5225883 Carter et al. Jul 1993 A
5255087 Nakamura et al. Oct 1993 A
5279298 Flower Jan 1994 A
5318023 Vari et al. Jun 1994 A
5318024 Kittrell et al. Jun 1994 A
5318869 Hashimoto et al. Jun 1994 A
5340592 Goodrich, Jr. et al. Aug 1994 A
5361769 Nilsson Nov 1994 A
5365057 Morley et al. Nov 1994 A
5371355 Wodecki Dec 1994 A
5375603 Feiler Dec 1994 A
5377676 Vari et al. Jan 1995 A
5377686 O'Rourke et al. Jan 1995 A
5394199 Flower Feb 1995 A
5419323 Kittrell et al. May 1995 A
5420628 Poulsen et al. May 1995 A
5421337 Richards-Kortum et al. Jun 1995 A
5421339 Ramanujam et al. Jun 1995 A
5424841 Van Gelder et al. Jun 1995 A
5430476 Häfele et al. Jul 1995 A
5437274 Khoobehi et al. Aug 1995 A
5438989 Hochman et al. Aug 1995 A
5453448 Narciso, Jr. Sep 1995 A
5465718 Hochman et al. Nov 1995 A
5491343 Brooker Feb 1996 A
5496369 Howard, III Mar 1996 A
5507287 Palcic et al. Apr 1996 A
5514127 Shanks May 1996 A
5519534 Smith et al. May 1996 A
5576013 Williams et al. Nov 1996 A
5590660 MacAulay et al. Jan 1997 A
5623930 Wright et al. Apr 1997 A
5627907 Gur et al. May 1997 A
5647368 Zeng et al. Jul 1997 A
5656498 Iijima et al. Aug 1997 A
5662644 Swor Sep 1997 A
5664574 Chance Sep 1997 A
5673701 Chance Oct 1997 A
5689241 Clarke, Sr. et al. Nov 1997 A
5699798 Hochman et al. Dec 1997 A
5707986 Miller et al. Jan 1998 A
5732707 Widder et al. Mar 1998 A
5741648 Hemstreet, III et al. Apr 1998 A
5743266 Levene et al. Apr 1998 A
5756541 Strong et al. May 1998 A
5785965 Pratt et al. Jul 1998 A
5803914 Ryals et al. Sep 1998 A
5827190 Palcic et al. Oct 1998 A
5845639 Hochman et al. Dec 1998 A
5851181 Talmor Dec 1998 A
5865754 Sevick-Muraca et al. Feb 1999 A
5910510 Strong et al. Jun 1999 A
5919616 Aurelian et al. Jul 1999 A
5927284 Borst et al. Jul 1999 A
5935942 Zeimer Aug 1999 A
5951980 Collen Sep 1999 A
5956435 Buzug et al. Sep 1999 A
5965356 Aurelian et al. Oct 1999 A
5999841 Aoyagi et al. Dec 1999 A
6008889 Zeng et al. Dec 1999 A
6013265 Aurelian Jan 2000 A
6021344 Lui et al. Feb 2000 A
6032070 Flock et al. Feb 2000 A
6054131 Aurelian Apr 2000 A
6069689 Zeng et al. May 2000 A
6074627 Dean et al. Jun 2000 A
6081612 Gutkowicz-Krusin et al. Jun 2000 A
6093149 Guracar et al. Jul 2000 A
6122042 Wunderman et al. Sep 2000 A
6140314 Zeimer Oct 2000 A
6148227 Wagnières et al. Nov 2000 A
6149671 Nordquist et al. Nov 2000 A
6162242 Peyman Dec 2000 A
6178340 Svetliza Jan 2001 B1
6179421 Pang Jan 2001 B1
6186628 Van de Velde Feb 2001 B1
6196226 Hochman et al. Mar 2001 B1
6207168 Aurelian Mar 2001 B1
6211953 Niino et al. Apr 2001 B1
6217848 Achilefu et al. Apr 2001 B1
6223069 Pfeiffer et al. Apr 2001 B1
6233480 Hochman et al. May 2001 B1
6241672 Hochman et al. Jun 2001 B1
6246901 Benaron Jun 2001 B1
6248727 Zeimer Jun 2001 B1
6263227 Boggett et al. Jul 2001 B1
6272374 Flock et al. Aug 2001 B1
6280386 Alfano et al. Aug 2001 B1
6293911 Imasizumi et al. Sep 2001 B1
6319273 Cheen et al. Nov 2001 B1
6331703 Yarnall et al. Dec 2001 B1
6335429 Cai et al. Jan 2002 B1
6351663 Flower et al. Feb 2002 B1
6351667 Godie Feb 2002 B1
6353750 Kimura et al. Mar 2002 B1
6399354 Knipe et al. Jun 2002 B1
6440950 Zeimer Aug 2002 B1
6443976 Flower et al. Sep 2002 B1
6447443 Keogh et al. Sep 2002 B1
6485413 Boppart et al. Nov 2002 B1
6498945 Alfheim et al. Dec 2002 B1
6544183 Thorn Leeson et al. Apr 2003 B2
6566641 Suda May 2003 B1
6603552 Cline et al. Aug 2003 B1
6621917 Vilser Sep 2003 B1
6631286 Pfeiffer et al. Oct 2003 B2
6671540 Hochman Dec 2003 B1
6757554 Rubinstein et al. Jun 2004 B2
6804549 Hayashi Oct 2004 B2
6821946 Goldspink et al. Nov 2004 B2
6840933 Pang et al. Jan 2005 B1
6853857 Pfeiffer et al. Feb 2005 B2
6882366 Kijima et al. Apr 2005 B1
6899675 Cline et al. May 2005 B2
6915154 Docherty et al. Jul 2005 B1
6936043 Peyman Aug 2005 B2
6944493 Alam et al. Sep 2005 B2
7113817 Winchester, Jr. et al. Sep 2006 B1
7236815 Richards-Kortum et al. Jun 2007 B2
7317554 Ueda et al. Jan 2008 B2
7364574 Flower Apr 2008 B2
7381400 Woltering Jun 2008 B2
7400753 Seino et al. Jul 2008 B2
7400755 West et al. Jul 2008 B2
7482318 Aurelian et al. Jan 2009 B2
7581191 Rice et al. Aug 2009 B2
7729750 Tromberg et al. Jun 2010 B2
7774048 Nakaoka et al. Aug 2010 B2
7881777 Docherty et al. Feb 2011 B2
7885438 Uppaluri et al. Feb 2011 B2
8036437 Arditi et al. Oct 2011 B2
8073224 Strobel et al. Dec 2011 B2
8144958 Nahm et al. Mar 2012 B2
8185176 Mangat et al. May 2012 B2
8194981 Suzuki Jun 2012 B2
8285353 Choi et al. Oct 2012 B2
8361775 Flower Jan 2013 B2
8406860 Dvorsky et al. Mar 2013 B2
8480579 Serov et al. Jul 2013 B2
8521260 Grinvald et al. Aug 2013 B2
8538107 Röttger Sep 2013 B2
8647605 Mangat et al. Feb 2014 B2
8725225 Golijanin et al. May 2014 B2
8892190 Docherty et al. Nov 2014 B2
8929974 Hauger et al. Jan 2015 B2
8965488 Dvorsky et al. Feb 2015 B2
9089601 Golijanin et al. Jul 2015 B2
9129366 Nahm et al. Sep 2015 B2
9241636 Koizumi et al. Jan 2016 B2
RE45916 Golijanin et al. Mar 2016 E
9351644 Nahm et al. May 2016 B2
9357931 Nahm et al. Jun 2016 B2
9421280 Mangat et al. Aug 2016 B2
9610021 Dvorsky et al. Apr 2017 B2
9642532 Fengler et al. May 2017 B2
9816930 Moriyama Nov 2017 B2
9936887 Dvorsky et al. Apr 2018 B2
10041042 Flower Aug 2018 B2
10219742 Dvorsky et al. Mar 2019 B2
10265419 Golijanin Apr 2019 B2
10278585 Ferguson, Jr. et al. May 2019 B2
20020025541 Nelson et al. Feb 2002 A1
20020038120 Duhaylongsod et al. Mar 2002 A1
20020099279 Pfeiffer et al. Jul 2002 A1
20020099295 Gil et al. Jul 2002 A1
20020146369 Goldenberg Oct 2002 A1
20020181752 Wallo et al. Dec 2002 A1
20020183621 Pfeiffer et al. Dec 2002 A1
20030032885 Rubinstein et al. Feb 2003 A1
20030050543 Hartmann Mar 2003 A1
20030060718 Alam et al. Mar 2003 A1
20030060722 Pfeiffer et al. Mar 2003 A1
20030064025 Yang et al. Apr 2003 A1
20030093064 Peyman May 2003 A1
20030093065 Peyman May 2003 A1
20030156252 Morris et al. Aug 2003 A1
20030187349 Kaneko et al. Oct 2003 A1
20030232016 Heinrich Dec 2003 A1
20030236458 Hochman Dec 2003 A1
20040002660 Mielekamp Jan 2004 A1
20040066961 Spreeuwers et al. Apr 2004 A1
20040077952 Rafter et al. Apr 2004 A1
20040109231 Haisch et al. Jun 2004 A1
20040156782 Alam et al. Aug 2004 A1
20040162489 Richards-Kortum et al. Aug 2004 A1
20040171827 Peng et al. Sep 2004 A1
20040174495 Levine Sep 2004 A1
20050019744 Bertuglia Jan 2005 A1
20050020891 Rubinstein et al. Jan 2005 A1
20050033145 Graham et al. Feb 2005 A1
20050069525 Mikael Mar 2005 A1
20050089866 Hinuma et al. Apr 2005 A1
20050107380 Nimmo et al. May 2005 A1
20050142556 Hoon et al. Jun 2005 A1
20050182321 Frangioni Aug 2005 A1
20050182327 Petty et al. Aug 2005 A1
20050182431 Hausen et al. Aug 2005 A1
20050182434 Docherty et al. Aug 2005 A1
20050187477 Serov et al. Aug 2005 A1
20050197583 Chance Sep 2005 A1
20050254008 Ferguson et al. Nov 2005 A1
20060013768 Woltering Jan 2006 A1
20060079750 Fauci et al. Apr 2006 A1
20060108509 Frangioni et al. May 2006 A1
20060118742 Levenson et al. Jun 2006 A1
20060147897 Grinvald et al. Jul 2006 A1
20060239921 Mangat et al. Oct 2006 A1
20060241499 Irion et al. Oct 2006 A1
20070121099 Matsumoto et al. May 2007 A1
20070122344 Golijanin May 2007 A1
20070122345 Golijanin May 2007 A1
20070203413 Frangioni Aug 2007 A1
20070254276 Deutsch et al. Nov 2007 A1
20080007733 Marks et al. Jan 2008 A1
20080015446 Mahmood et al. Jan 2008 A1
20080025918 Frangioni et al. Jan 2008 A1
20080044073 Bernhardt et al. Feb 2008 A1
20080081990 Berenfeld et al. Apr 2008 A1
20080161744 Golijanin et al. Jul 2008 A1
20080221421 Choi et al. Sep 2008 A1
20080221648 Flower Sep 2008 A1
20080239070 Westwick et al. Oct 2008 A1
20080319309 Bredno et al. Dec 2008 A1
20090005693 Brauner et al. Jan 2009 A1
20090042179 Peltie et al. Feb 2009 A1
20090048516 Yoshikawa et al. Feb 2009 A1
20090054788 Hauger et al. Feb 2009 A1
20090118623 Serov et al. May 2009 A1
20090137902 Frangioni et al. May 2009 A1
20090252682 Hillman Oct 2009 A1
20090297004 Baumgart Dec 2009 A1
20100016669 Takaoka et al. Jan 2010 A1
20100022898 Rubinstein et al. Jan 2010 A1
20100036217 Choi et al. Feb 2010 A1
20100041999 Schuhrke et al. Feb 2010 A1
20100061604 Nahm et al. Mar 2010 A1
20100069759 Schuhrke et al. Mar 2010 A1
20100099961 Hubner et al. Apr 2010 A1
20100222673 Mangat et al. Sep 2010 A1
20100286529 Carroll et al. Nov 2010 A1
20110001061 Ishihara Jan 2011 A1
20110013002 Thompson et al. Jan 2011 A1
20110063427 Fengler et al. Mar 2011 A1
20110071403 Sevick-Muraca et al. Mar 2011 A1
20110098685 Flower Apr 2011 A1
20110306877 Dvorsky et al. Dec 2011 A1
20120026325 Bunker et al. Feb 2012 A1
20120078093 Flower Mar 2012 A1
20120252699 Jaffrey et al. Apr 2012 A1
20120165627 Yamamoto Jun 2012 A1
20120165662 Nahm et al. Jun 2012 A1
20120271176 Moghaddam et al. Oct 2012 A1
20130203082 Gonda et al. Aug 2013 A1
20130230866 Miyashita et al. Sep 2013 A1
20130245456 Ferguson, Jr. et al. Sep 2013 A1
20130286176 Westwick et al. Oct 2013 A1
20130296715 Lasser et al. Nov 2013 A1
20130342674 Dixon Dec 2013 A1
20130345560 Ferguson, Jr. et al. Dec 2013 A1
20140099007 Sarkar et al. Apr 2014 A1
20140308656 Flower Oct 2014 A1
20140316262 Havens Oct 2014 A1
20150112192 Docherty et al. Apr 2015 A1
20150112193 Docherty et al. Apr 2015 A1
20150196208 Dvorsky et al. Jul 2015 A1
20150230710 Nahm et al. Aug 2015 A1
20150230715 Nahm et al. Aug 2015 A1
20160038027 Brzozowski et al. Feb 2016 A1
20160041098 Hirawake Feb 2016 A1
20160199515 Flower Jul 2016 A1
20160371834 Watanabe Dec 2016 A1
20170039710 Minai et al. Feb 2017 A1
20170303800 Flower et al. Oct 2017 A1
20180020933 Dvorsky et al. Jan 2018 A1
20180104362 Golijanin et al. Apr 2018 A1
20180220907 Dvorsky et al. Aug 2018 A1
20180234603 Moore et al. Aug 2018 A1
20180369426 Flower et al. Dec 2018 A1
Foreign Referenced Citations (163)
Number Date Country
409451 Aug 2002 AT
2212257 Aug 1996 CA
2413033 Mar 2000 CA
2711560 Jul 2009 CA
2913692 Jan 2015 CA
1049781 Mar 1991 CN
1200174 Nov 1998 CN
1399528 Feb 2003 CN
101264014 Sep 2008 CN
101451953 Jun 2009 CN
102288589 Dec 2011 CN
102405212 Apr 2012 CN
102436648 May 2012 CN
103608662 Feb 2014 CN
3906860 Sep 1989 DE
19608027 Sep 1996 DE
10028233 Jan 2002 DE
10120980 Nov 2002 DE
69727220 Dec 2004 DE
102005044531 Mar 2007 DE
0091805 Oct 1983 EP
0215772 Mar 1987 EP
0512965 Nov 1992 EP
0792618 Sep 1997 EP
0807402 Nov 1997 EP
0826335 Mar 1998 EP
1677097 Jul 2006 EP
1761171 Mar 2007 EP
1874181 Jan 2008 EP
2944104 Oct 2010 FR
2203831 Oct 1988 GB
S52-34584 Mar 1977 JP
S58-222331 Dec 1983 JP
S59-069721 Apr 1984 JP
S59-070903 Apr 1984 JP
H01-236879 Sep 1989 JP
02-200237 Aug 1990 JP
H03-115958 May 1991 JP
04-297236 Oct 1992 JP
H05-264232 Oct 1993 JP
H06-007353 Jan 1994 JP
06-335451 Dec 1994 JP
H07-043303 Feb 1995 JP
07-065154 Mar 1995 JP
07-079955 Mar 1995 JP
H07-155285 Jun 1995 JP
H07-155286 Jun 1995 JP
H07-155290 Jun 1995 JP
H07-155291 Jun 1995 JP
H07-155292 Jun 1995 JP
07-222712 Aug 1995 JP
H07-204156 Aug 1995 JP
H07-222723 Aug 1995 JP
H07-250804 Oct 1995 JP
H07-250812 Oct 1995 JP
08-024227 Jan 1996 JP
H08-224208 Sep 1996 JP
H08-224209 Sep 1996 JP
H08-224240 Sep 1996 JP
H09-120033 May 1997 JP
H09-305845 Nov 1997 JP
H09-308609 Dec 1997 JP
H09-309845 Dec 1997 JP
H10-500479 Jan 1998 JP
H10-503480 Mar 1998 JP
H10-085222 Apr 1998 JP
H10-104070 Apr 1998 JP
H10-151104 Jun 1998 JP
H10-506440 Jun 1998 JP
H10-506550 Jun 1998 JP
H10-201700 Aug 1998 JP
H10-201707 Aug 1998 JP
H11-137517 May 1999 JP
H11-155812 Jun 1999 JP
H11-509748 Aug 1999 JP
2001-198079 Jul 2001 JP
2002-219129 Aug 2002 JP
2003-510121 Mar 2003 JP
2003-144401 May 2003 JP
2003-187226 Jul 2003 JP
2003-329589 Nov 2003 JP
2004-528917 Sep 2004 JP
2004-325200 Nov 2004 JP
2006-503620 Feb 2006 JP
2006-192280 Jul 2006 JP
2007-021006 Feb 2007 JP
3896176 Mar 2007 JP
2008-023113 Feb 2008 JP
2008-525126 Jul 2008 JP
2008-220926 Sep 2008 JP
2008-535600 Sep 2008 JP
2008-231113 Oct 2008 JP
2009-095683 May 2009 JP
2009-291554 Dec 2009 JP
2010-505582 Feb 2010 JP
2010-521267 Jun 2010 JP
2011-509768 Mar 2011 JP
2011-519589 Jul 2011 JP
2011-528918 Dec 2011 JP
5918532 May 2016 JP
2016-521612 Jul 2016 JP
90-0005434 Jul 1990 KR
2002-0064287 Aug 2002 KR
2288633 Dec 2006 RU
WO-198602730 May 1986 WO
WO-199010219 Sep 1990 WO
WO-199012536 Nov 1990 WO
WO-199325141 Dec 1993 WO
WO-199412092 Jun 1994 WO
WO-199500171 Jan 1995 WO
WO-199526673 Oct 1995 WO
WO-199609435 Mar 1996 WO
WO-199609792 Apr 1996 WO
WO-199618415 Jun 1996 WO
WO-199623524 Aug 1996 WO
WO-199639925 Dec 1996 WO
WO-199708538 Mar 1997 WO
WO-199824360 Jun 1998 WO
WO-199830144 Jul 1998 WO
WO-199846122 Oct 1998 WO
WO-199900053 Jan 1999 WO
WO-199947940 Sep 1999 WO
WO-199953832 Oct 1999 WO
WO-200042910 Jul 2000 WO
WO-200047107 Aug 2000 WO
WO-200108552 Feb 2001 WO
WO-200117561 Mar 2001 WO
WO-200122870 Apr 2001 WO
WO-200139764 Jun 2001 WO
WO-200169244 Sep 2001 WO
WO-200180734 Nov 2001 WO
WO-200182786 Nov 2001 WO
WO-2002061390 Aug 2002 WO
WO-2003006658 Jan 2003 WO
WO-2004006963 Jan 2004 WO
WO-2004052195 Jun 2004 WO
WO-2005026319 Mar 2005 WO
WO-2005034747 Apr 2005 WO
WO-2005036143 Apr 2005 WO
WO-2005079238 Sep 2005 WO
WO-2006111836 Oct 2006 WO
WO-2006111909 Oct 2006 WO
WO-2006116634 Nov 2006 WO
WO-2006119349 Nov 2006 WO
WO-2006121631 Nov 2006 WO
WO-2006121631 Nov 2006 WO
WO-2006123742 Nov 2006 WO
WO-2007028032 Mar 2007 WO
WO-2008039968 Apr 2008 WO
WO-2008044822 Apr 2008 WO
WO-2008070269 Jun 2008 WO
WO-2008070269 Jun 2008 WO
WO-2008087869 Jul 2008 WO
WO-2009046985 Apr 2009 WO
WO-2009046985 Apr 2009 WO
WO-2009048660 Apr 2009 WO
WO-2009092162 Jul 2009 WO
WO-2009127972 Oct 2009 WO
WO-2012038824 Mar 2012 WO
WO-2012096878 Jul 2012 WO
WO-2013190391 Dec 2013 WO
WO-2015001427 Jan 2015 WO
WO-2013002350 Feb 2015 WO
Non-Patent Literature Citations (499)
Entry
Japanese Office Action dated May 7, 2018 for Japanese Patent Application No. 2017-516925 filed on Mar. 28, 2017, four pages.
Akintunde, A. et al. (Oct.-Nov. 1992). “Quadruple Labeling of Brain-Stem Neurons: A Multiple Retrograde Fluorescent Tracer Study of Axonal Collateralization,” Journal of Neuroscience Methods 45(1-2):15-22.
Alander, J.T. et al. (Jan. 1, 2012). “A Review of Indocyanine Green Fluorescent Imaging in Surgery,” International Journal of Biomedical Imaging 2012:1-26, article ID 940585.
Alfano et al. (Oct. 1987). “Fluorescence Spectra from Cancerous and Normal Human Breast and Lung Tissues,” IEEE Journal of Quantum Electronics QE-23(10):1806-1811.
Alm, A. et al. (Jan. 1, 1973). “Ocular and Optic Nerve Blood Flow at Normal and Increased Intraocular Pressures in Monkeys (Macaca irus): A Study with Radioactively Labelled Microspheres Including Flow Determinations in Brain and Some Other Tissues,” Experimental Eye Research 15(1):15-29.
Alonso-Burgos, A. et al. (2006). “Preoperative planning of deep inferior epigastric artery perforator flap reconstruction with multi-slice-CT angiography: imaging findings and initial experience,” Journal of Plastic, Reconstructive & Aesthetic Surgery 59:585-593.
Alvarez, F. J. et al. (Apr. 1996). “Behaviour of Isolated Rat and Human Red Blood Cells Upon Hypotonic-Dialysis Encapsulation of Carbonic Anhydrase and Dextran,” Biotechnology and Applied Biochemistry 23(2):173-179.
Ancalmo, N. et al. (1997). “Minimally invasive coronary artery bypass surgery: really minimal?” Ann. Thorac. Surg. 64:928-929.
Andersson-Engels, S. et al. (1991). “Fluorescence Characteristics of Atherosclorotic Plaque and Malignant Tumors,” in Optical Methods for Tumor Treatment and Early Diagnosis: Mechanisms and Techniques, T. J. Dougherty (Ed.), The Society of Photo-optical Instrumentation Engineers (SPIE) 1426:31-43, fourteen pages.
Andersson-Engels, S. et al. (Mar. 1989). “Tissue Diagnostics Using Laser-Induced Fluorescence,” Berichte der Bunsengesellschaft für physikalische Chemie 93(3):335-342.
Angelov, D.N. et al. (Apr. 1999). “Contralateral Trigeminal Nerve Lesion Reduces Polyneuronal Muscle Innervation after Facial Nerve Repair in Rats,” European Journal of Neuroscience 11(4):1369-1378.
Annese, V. et al. (2005). “RBCs-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients—a Pilot Uncontrolled Study,” American Journal of Gastroenterol. 100:1370-1375.
Argus-50/CA, Inter cellular CA2+ (calcium ion) Image Analysis system (Feb. 1992). “Observation and 2-dimensional analysis of Ca2+ concentration distribution. Fura-2 and Indo-1 compatible. Ca2+ concentrations are calculated from the fluorescence ratio,” pp. 1-10.
Author Unknown. (Jun. 4, 2008).“Invitrogen,” Material Safety Data Sheet, p. 1-4.
Awano, T. et al. (Jun. 2010). “Intraoperative EC-IC Bypass Blood Flow Assessment with Indocyanine Green Angiography in Moyamoya and Non-moyamoya Ischemic Stroke,” World Neurosurg. 73(6):668-674.
Azuma, R. et al. (2008, presented in part Jun. 2007). “Detection of Skin Perforators by Indocyanine Green Fluorescence Nearly Infrared Angiography,” PRS Journal 122(4):1062-1067.
Balacumarswami, L. et al. (Aug. 2004). “Does Off-Pump Total Arterial Grafting Increase the Incidence of Intraoperative Graft Failure?,” The Journal of Thoracic and Cardiovascular Surgery 128(2):238-244.
Barton, J.K. et al. (1999) “Simultaneous irradiation and imaging of blood vessels during pulsed laser delivery,” Lasers in Surgery and Medicine 24(3):236-243.
Bassingthwaighte, J.B. et al. (Apr. 1974). “Organ Blood Flow, Wash-in, Washout, and Clearance of Nutrients and Metabolites,” Mayo Clin. Proc. 49(4):248-255.
Batliwala, H. et al. (Apr. 15, 1995). “Methane-Induced Haemolysis of Human Erythrocytes,” Biochemical J. 307(2):433-438.
Bek, T. (1999). “Diabetic Maculopathy Caused by Disturbances in Retinal Vasomotion: A New Hypothesis,” Acta Ophthalmologica Scandinavica 77:376-380.
Benson, R.C. et al. (1978). “Fluorescence Properties of Indocyanine Green as Related to Angiography,” Phys. Med. Biol. 23(1):159-163.
Black's Medical Dictionary, “Perfusion,” 42nd Edition (2009), two pages.
Boer, F.et al. (1994). “Effect of Ventilation on First-Pass Pulmonary Retention of Alfentaril and Sufentanil in Patients Undergoing Coronary Artery Surgery,” British Journal Anesthesia 73:458-463.
Boldt, .J. et al. (Feb. 1990). “Lung management during cardiopulmonary bypass: influence on extravascular lung water,” Journal of Cardiothoracic Anesthesia 4(1):73-79.
Boldt, J. et al. (1991). “Does the technique of cardiopulmonary bypass affect lung water content?” European Journal of Cardio-Thoracic Surgery 5:22-26.
Bütter, A. et al. (May 2005). “Melanoma in Children and the Use of Sentinel Lymph Node Biopsy,” Journal of Pediatric Surgery 40(5):797-800.
C2741, Compact High Performance video camera for industrial applications with Built-in contrast enhancement circuit, Jun. 1998.
Canada Health. (1997). “Coronary Bypass Surgery and Angioplasty, 1982-1995, Heart Disease and Stroke in Canada,” Canada Health, located at <http:/www.hc-sc.gc.ca/hpb>, eighty two pages.
Coffey, J.H. et al. (1984). “Evaluation of Visual Acuity During Laser Photoradiation Therapy of Cancer,” Lasers in Surgery and Medicine 4(1):65-71.
Conley, M.P. et al. (Oct. 2004). “Anterograde Transport of Peptide-Conjugated Fluorescent Beads in the Squid Giant Axom Identifies a Zip-Code for Synapse,” Biological Bulletin 207(2):164, one page.
Costa, R.A. et al. (Oct. 2001). “Photodynamic Therapy with Indocyanine Green for Occult Subfoveal Choroidal Neovascularization Caused by Age-Related Macular Degeneration,” Curr. Eye Res. 23(4):274-275.
Cothren, R.M. et al. (Mar. 1990). “Gastrointestinal Tissue Diagnosis by Laser-Induced Fluorescence Spectroscopy at Endoscopy,” Gastrointestinal Endoscopy 36(2):105-111.
Dail, W.G. et al. (Oct. 1999). “Multiple Vasodilator Pathways from the Pelvic Plexus to the Penis of the Rat,” International Journal of Impotence Research 11(5):277-285.
Dan, A.G. et al. (Nov. 2004). “1% Lymphazurin vs 10% Fluorescein for Sentinel Node Mapping in Colorectal Tumors,” Arch Surg. 139(11):1180-1184.
Daniels, G. et al. (Apr. 2007). “Towards Universal Red Blood Cell,” Nature Biotechnology 25(4):427-428.
De Flora, A. (Sep. 1986). “Encapsulation of Adriamycin in human erythrocytes,” Proc. Natl. Acad. Sci., USA 83(18):7029-7033.
Declaration of Brian Wilson dated Aug. 22, 2017 for Inter Partes Review No. IPR2017-01426, twelve pages, [Exhibit 2002].
Definition of “Expose,” Excerpt of Merriam Webster's Medical Desk Dictionary (1993), four pages, [Exhibit 2004].
Definition of “Graft,” Excerpt of Stedman's Medical Dictionary for the Health Professions and Nursing; 6th Ed. (2008), three pages, [Exhibit 2003].
De-Grand, A.M. et al. (Dec. 2003). “An Operational Near Infrared Fluorescence Imaging System Prototype for Large Animal Surgery,” Technology in Cancer Research & Treatment 2(6):1-10.
Deloach, J.R. (ed.) et al. (1985). Red Blood Cells as Carriers for Drugs. A Method for Disseminating Chemotherapeutics, Hormones, Enzymes and Other Therapeutic Agents via the Circulatory System, Karger, Basel, CH, pp. v-vii, (Table of Contents).
Deloach, J.R. (Jun. 1983). “Encapsulation of Exogenous Agents in Erythrocytes and the Circulating Survival of Carrier Erythrocytes,” Journal of Applied Biochemistry 5(3):149-157.
Demos (May/Jun. 2004). “Near-Infrared Autofluorescence Imaging for Detection of Cancer,” Journal of Biomedical Optics 9(3):587-592.
Desai, N.D. et al. (Oct. 18, 2005, e-published on Sep. 28, 2005) “Improving the Quality of Coronary Bypass Surgery with Intraoperative Angiography,” Journal of the American College of Cardiology 46(8):1521-1525.
Detter, C. et al. (Aug. 1, 2007). “Fluorescent Cardiac Imaging: A Novel Intraoperative Method for Quantitative Assessment of Myocardial Perfusion During Graded Coronary Artery Stenosis,” Circulation 116(9):1007-1014.
Detter, C. et al. (Jun. 2011). “Near-Infrared Fluorescence Coronary Angiography: A New Noninvasive Technology for Intraoperative Graft Patency Control.” The Heart Surgery Forum #2001-6973 5(4):364-369.
Dietz, F.B. et al. (Feb. 2003). “Indocyanine Green: Evidence of Neurotoxicity in Spinal Root Axons,” Anesthesiology 98(2):516-520.
Digital CCD Microscopy (date unknown). Chapter 14, pp. 259-282.
Dougherty, T.J. et al. (1990). “Cutaneous Phototoxic Occurrences in Patients Receiving Photofrin,” Lasers in Surgery and Medicine 10(5):485-488.
Draijer, M.J. et al. (Jun. 17-19, 2007). “Laser Doppler Perfusion Imaging with a High-Speed CMOS-Camera,” in Novel Optical Instrumentation for Biomedical Applications III, C. Depeursinge, ed., Proceedings of SPIE-OSA Biomedical Optics (Optical Society of America, 2007), SPIE-OSA, 6631:0N1-0N7, nine pages.
Dünne, A. et al. (Nov. 2001).“Value of Sentinel lymphonodectomy in Head and Neck Cancer Patients without Evidence of Lymphogenic Metastatic Disease,” Auris Nasus Larynx 28(4):339-344.
Ekstrand, M.I. et al. (Feb. 14, 2008). “The Alpha-Herpesviruses: Molecular Pathfinders in Nervous System Circuits,” Trends in Molecular Medicine, Elsevier Current Trends 14(3):134-140.
Emery R.W. et al. (Aug. 1996). “Revascularization Using Angioplasty and Minimally Invasive Techniques Documented by Thermal Imaging,” The Annals of Thoracic Surgery 62(2):591-593.
Enquist, L.W. et al. (2002). “Directional Spread of an α-Herpesvirus in the Nervous System,” Veterinary Microbiology 86:5-16.
Eren, S. et al. (Dec. 1995). “Assessment of Microcirculation of an Axial Skin Flap Using Indocyanine Green Fluorescence Angiography,” Plast. Reconstr. Surg. 96(7):1636-1649. [Exhibit 1008].
Falk, T. et al. (Apr. 15, 2001). “A Herpes Simplex Viral Vector Expressing Green Fluorescent Protein can be Used to Visualize Morphological Changes in High-density Neuronal Culture,” Electronic Journal of Biotechnology 4(1):34-45.
Flower, R. et al. (Apr.-Jun. 1999). “Effects of free and liposome-encapsulated hemoglobin on choroidal vascular plexus blood flow, using the rabbit eye as a model system,” European Journal of Ophthalmology 9(2):103-114.
Flower, R.W. (1992). “Choroidal Angiography Today and Tomorrow,” Retina 12(3):189-190.
Flower, R.W. (Apr. 2000). “Experimental Studies of Indocyanine Green Dye-Enhanced Photocoagulation of Choroidal Neovascularization Feeder Vessels,” American Journal of Ophthalmology 129(4):501-512.
Flower, R.W. (Aug. 2002). “Optimizing Treatment of Choroidal Neovascularization Feeder Vessels Associated with Age-Related Macular Degeneration,” American Journal of Ophthalmology 134(2):228-239.
Flower, R.W. (Dec. 1973). “Injection Technique for Indocyanine Green and Sodium Fluorescein Dye Angiography of the Eye,” Investigative Opthamology 12(12):881-895.
Flower, R.W. (Sep. 1, 1994). “Does Preinjection Binding of Indocyanine Green to Serum Actually Improve Angiograms?,” Arch Ophthalmol. 112(9):1137-1139.
Flower, R.W. et al. (Aug. 1977). “Quantification of Indicator Dye Concentration in Ocular Blood Vessels,” Exp. Eye Res. 25(2):103-111.
Flower, R.W. et al. (Dec. 1, 2008, e-published Aug. 15, 2008). “Observation of Erythrocyte Dynamics in the Retinal Capillaries and Choriocapillaris Using ICG-Loaded Erythrocyte Ghost Cells,” Investigative Ophthalmology, & Visual Science 49(12):5510-5516.
Flower, R.W. et al. (Mar. 26, 2008-Mar. 29, 2008). “Observation of Erythrocyte Dynamics in the Retinal Capillaries and Choriocapillaris Using ICG-Loaded Erythrocyte Ghost Cells,” Annual Meeting of the Macula Society, Abstract No. XP002535355, Palm Beach, FL, USA, fourteen pages, (Schedule of the Meeting only).
Forrester et al. (Nov. 1, 2002). “Comparison of Laser Speckle and Laser Doppler Perfusion Imaging: Measurement in Human Skin and Rabbit Articular Tissue,” Medical and Biological Engineering and Computing 40(6):687-697.
Frangioni, J.V. (Oct. 2003). “In Vivo Near-Infrared Fluorescence Imaging,” Current Opinion in Chemical Biology 7(5):626-634.
Frenzel H. et al. (Apr. 18, 2008). “In Vivo Perfusion Analysis of Normal and Dysplastic Ears and its Implication on Total Auricular Reconstruction,” Journal of Plastic, Reconstructive and Aesthetic Surgery 61(Supplement1):S21-S28.
Fritzsch, B. et al. (Aug. 1991).“Sequential Double Labeling With Different Fluorescent Dyes Coupled to Dextran Amines as a Tool to Estimate the Accuracy of Tracer Application and of Regeneration,” Journal of Neuroscience Methods 39(1):9-17.
Gagnon, A.R. et al. (2006). “Deep and Superficial Inferior Epigastric Artery Perforator Flaps,” Cirugia Plástica Ibero-Latinoamericana 32(4):7-13.
Gardner, T.J. (1993). “Coronary Artery Disease and Ventricular Aneurysms,” in Surgery, Scientific Principles and Practice, Greenfield, L.J. (ed.) et al., J.B. Lippincott Co., Philadelphia, PA, pp. 1391-1411, twenty three pages.
Garrett, W.T. et al. (Jul. 8, 1991). “Fluoro-Gold's Toxicity makes it Inferior to True Blue for Long-Term Studies of Dorsal Root Ganglion Neurons and Motoneurons,” Neuroscience Letters 128(1):137-139.
Geddes, C. D. et al. (2003, e-published on Mar. 20, 2003). “Metal-Enhanced Fluorescence (MEF) Due to Silver Colloids on a Planar Surface: Potential Applications of Indocyanine Green to in Vivo Imaging,” Journal of Physical Chemistry A 107(18):3443-3449.
Gipponi, M. et al. (Mar. 1, 2004). “New Fields of Application of the Sentinel Lymph Node Biopsy in the Pathologic Staging of Solid Neoplasms: Review of Literature and Surgical Perspectives,” Journal of Surgical Oncology 85(3):171-179.
Giunta, R.E. et al. (Jul. 2005). “Prediction of Flap Necrosis with Laser Induced Indocyanine Green Fluorescence in a Rat Model,” British Journal of Plastic Surgery 58(5):695-701.
Giunta, R.E. et al. (Jun. 2000). “The Value of Preoperative Doppler Sonography for Planning Free Perforator Flaps,” Plastic and Reconstructive Surgery 105(7):2381-2386.
Glossary, Nature, downloaded from the internet <http://www.nature.com/nrg/journal/v4/nl0/glossary/nrgl 183_glossary.html>> HTML on Jun. 30, 2014.
Glover, J.C. et al. (Nov. 1986). “Fluorescent Dextran-Amines Used as Axonal Tracers in the Nervous System of the Chicken Embryo,” Journal of Neuroscience Methods 18(3):243-254.
Goldstein, J.A. et al. (Dec. 1998). “Intraoperative Angiography to Assess Graft Patency After Minimally Invasive Coronary Bypass,” Ann. Thorac. Surg. 66(6):1978-1982. [Exhibit 1007].
Gothoskar A.V. (Mar. 2004). “Resealed Erythrocytes: A Review,” Pharmaceutical Technology pp. 140, 142, 144, 146, 148, 150, 152 and 154-158, twelve pages.
Granzow, J.W. et al. (Jul. 2007).“Breast Reconstruction with Perforator Flaps” Plastic and Reconstructive Surgery 120(1):1-12.
Green, H.A. et al. (Jan. 1992). “Burn Depth Estimation Using Indocyanine Green Fluorescence,” Arch Dermatol 128(1):43-49.
Haglund, M. et al. (Feb. 1996). “Enhanced Optical Imaging of Human Gliomas and Tumor Margins,” Neurosurgery 38(2):308-317.
Haglund, M.M. et al. (Nov. 1994). “Enhanced Optical Imaging of Rat Gliomas and Tumor Margins,” Neurosurgery 35(5):930-941.
Hallock, G.G. (Jul. 2003). “Doppler sonography and color duplex imaging for planning a perforator flap,” Clinics in Plastic Surgery 30(3):347-357.
Hamamatsu Brochure. (May 1997). Specifications for Real-time Microscope Image Processing System: ARGUS-20 with C2400-75i. [Exhibit 1006].
Hamamatsu. (Date unknown). Microscope Video Camera, for Fluorescent Observation, Easy Fluorescent Image Analysis C2400-731, -751 Series a CCD Camera.
Hayashi, J. et al. (Nov. 1993). “Transadventitial Localization of Atheromatous Plaques by Fluorescence Emission Spectrum Analysis of Mono-L Aspartyl-Chlorin e6,” Cardiovascular Research 27(11):1943-1947.
Hayata, Y. et al. (Jul. 1982). “Fiberoptic Bronchoscopic Laser Photoradiation for Tumor Localization in Lung Cancer,” Chest 82(1):10-14.
He, Z. (Feb. 2009). “Fluorogold Induces Persistent Neurological Deficits and Circling Behavior in Mice Over-Expressing Human Mutant Tau,” Current Neurovascular Research 6(1):54-61.
Herts, B.R. (May 2003). “Imaging for Renal Tumors,” Current Opin.. Urol. 13(3):181-186.
Hirano, T. et al. (1989). “Photodynamic Cancer Diagnosis and Treatment System Consisting of Pulse Lasers and an Endoscopic Spectro-Image Analyzer,” Laser in Life Sciences 3(2):99-116.
Holm, C. et al. (2002). “Monitoring Free Flaps Using Laser-Induced Fluorescence of Indocyanine Green: A Preliminary Experience,” Microsurgery 22(7):278-287.
Holm, C. et al. (Apr. 2003, e-published on Feb. 25, 2003). “Laser-Induced Fluorescence of Indocyanine Green: Plastic Surgical Applications,” European Journal of Plastic Surgery 26(1):19-25.
Holm, C. et al. (Dec. 1, 2002). “Intraoperative Evaluation of Skin-Flap Viability Using Laser-Induced Fluorescence of Indocyanine Green”, British Journal of Plastic Surgery 55(8):635-644.
Humblet, V. et al. (Oct. 2005). “High-Affinity Near-Infrared Fluorescent Small-Molecule Contrast Agents for In Vivo Imaging of Prostate-Specific Membrane Antigen,” Molecular Imaging 4(4):448-462.
Hung, J. et al.(1991). “Autofluorescence of Normal and Malignant Bronchial Tissue,” Lasers in Surgery and Medicine 11(2):99-105.
Hyvärinen, L. et al. (1980). “Indocyanine Green Fluorescence Angiography.” Acta ophthalmologica 58(4):528-538. [Exhibit 1014].
Ikeda, S. (Jul. 1989). “Bronichial Telivision Endoscopy,” Chest 96(1):41S-42S.
Jaber, S.F. et al. (Sep. 1998). “Role of Graft Flow Measurement Technique in Anastomotic Quality Assessment in Minimally Invasive CABG,” Ann. Thorac. Surg. 66(3):1087-1092.
Jagoe, J.R. et al. (1989). “Quantification of retinal damage during cardiopulmonary bypass,” Third International Conference on Image Processing and its Applications (Conf. Publ. No. 307), IEE, pp. 319-323.
Jamis-Dow, C.A. et al. (Mar. 1996). “Small (< or = 3-cm) Renal Masses: Detection with CT versus US and Pathologic Correlation,” Radiology 198(3):785-788.
Jolion, J. et al. (Aug. 1991). “Robust Clustering with Applications in Computer Vision,” IEEE Transactions on Pattern Analysis and Machine Intelligence 13(8):791-802.
Kamolz, L.-P. et al. (Dec. 2003). “Indocyanine Green Video Angiographies Help to Identify Burns Requiring Operation,” Burns 29(8):785-791.
Kapadia, C.R. et al. (Jul. 1990). “Laser-Induced Fluorescence Spectroscopy of Human Colonic Mucosa. Detection of Adenomatous Transformation,” Gastroenterology 99(1):150-157.
Kato, H. et al. (Jun. 1985). “Early Detection of Lung Cancer by Means of Hematoporphyrin Derivative Fluorescence and Laser Photoradiation,” Clinics in Chest Medicine6(2):237-253.
Kato, H. et al. (Jun. 1990). “Photodynamic Diagnosis in Respiratory Tract Malignancy Using an Excimer Dye Laser System,” Journal of Photochemistry and Photobiology, B. Biology 6(1-2):189-196.
Keon, W.J. et al. (Dec. 1979). “Coronary Endarterectomy: An Adjunct to Coronary Artery Bypass Grafting,” Surgery 86(6):859-867.
Kim, S. et al. (2004, e-published Dec. 7, 2003). “Near-Infrared Fluorescent Type II Quantum Dots for Sentinel Lymph Node Mapping,” Nature Biotechnology 22(1):93-97.
Kiryu, J. et al. (Sep. 1994). “Noninvasive Visualization of the Choriocapillaris and its Dynamic Filling,” Investigative Ophthalmology & Visual Science 35(10):3724-3731.
Kitai, T. et al. (Jul. 2005). “Fluorescence Navigation with Indocyanine Green for Detecting Sentinel Lymph Nodes in Breast Cancer,” Breast Cancer 12(3):211-215.
Kleszcyńska, H. et al. (Mar. 2005). “Hemolysis of Erythrocytes and Erythrocyte Membrane Fluidity Changes by New Lysosomotropic Compounds,” Journal of Fluorescence 15(2):137-141.
Köbbert, C. et al. (Nov. 2000). “Current Concepts in Neuroanatomical Tracing,” Progress in Neurobiology 62(4):327-351.
Kokaji, K. et al. (Date Unknown). “Intraoperative Quality Assessment by Using Fluorescent Imaging in Off-pump Coronary Artery Bypass Grafting,” The Department of Cardiovascular Surgery, University of Keio, Tokyo, Japan. (Abstract only).
Kömürcü, F. et al. (Feb. 2005). “Management Strategies for Peripheral Iatrogenic Nerve Lesions,” Annals of Plastic Surgery 54(2):135-139.
Krishnan, K. G. et al. (Apr. 1, 2005). “The Role of Near-Infrared Angiography in the Assessment of Post-Operative Venous Congestion in Random Pattern, Pedicled Island and Free Flaps”, British Journal of Plastic Surgery 58(3):330-338.
Kuipers, J.A. et al. (1999). “Recirculatory and Compartmental Pharmacokinetic Modeling of Alfentanil Pigs, the Influence of Cardiac Output,” Anesthesiology 90(4):1146-1157.
Kupriyanov, V.V. et al. (Nov. 2004). “Mapping Regional Oxygenation and Flow in Pig Hearts In Vivo Using Near-infrared Spectroscopic Imaging,” Journal of Molecular and Cellular Cardiology 37(5):947-957.
Kurihara, K. et al. (Jun. 1984). “Nerve Staining with Leucomethylene Blue: An Experimental Study,” Plastic and Reconstruction Surgery 73(6):960-964.
Kyo, S. “Use of Ultrasound Cardiology during Coronary Artery Bypass Surgery,” Heart and Blood Vessel Imaging II, three pages.
Lam, S. et al. (1991). “Mechanism of Detection of Early Lung Cancer by Ratio Fluorometry,” Lasers in Life Sciences 4(2):67-73.
Lam, S. et al. (Feb. 1990). “Detection of Early Lung Cancer Using Low Dose Photofrin II,” Chest 97(2):333-337.
Lam, S. et al. (Jul. 1, 1990). “Detection of Lung Cancer by Ratio Fluorometry With and Without Photofrin II,” Proc. SPIE—Optical Fibers in Medicine V 1201:561-568.
Lam, S. et al. (Nov. 1-4, 1990). “Fluorescence Imaging of Early Lung Cancer,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society 12(3):1142-1143.
Lam, S.C. et al. (1993). “Fluorescence Detection,” Chapter 20 in Lung Cancer, Roth, J.A. (ed.), et al., Blackwell Scientific Publications Inc., 238 Main Street, Cambridge, Massachusetts, 02142, pp. 325-338, sixteen pages.
Lanciego, J.L. et al. (Jun. 1998). “Multiple Neuroanatomical Tracing in Primates,” Brain Research Protocols 2(4):323-332.
Lanciego, J.L. et al. (Oct. 1998). “Multiple Axonal Tracing: Simultaneous Detection of Three Tracers in the Same Section,” Histochemistry and Cell Biology 110(5):509-515.
Laub, G.W. et al. (Nov. /Dec. 1989). “Experimental Use of Fluorescein for Visualization of Coronary Arteries,” Vascular and Endovascular Surgery 23(6):454-457.
Lee, E.T. et al. (Mar. 1997). “A New Method for Assessment of Changes in Retinal Blood Flow,” Medical Engineering & Physics 19(2):125-130.
Leissner, J. et al. (Jan. 2004). “Extended Radical Lymphadenectomy in Patients with Urothelial Bladder Cancer: Results of a Prospective Multicenter Study,” The Journal of Urology 171(1):139-144.
Leithner, “Untersuchung der Sauerstoffkonzentrationsveranderungen in der Mikrozirkulation des Hirnkortex von Ratten bei funktioneller Stimulation mittels Phosphorescence Quenching,” [dissertation], Jul. 14, 2003; retrieved from the Internet: <http://edoc.hu-berlin.de/d issertationen/leith ner-ch ristoph-2003-07-14/> [English Abstract and Machine Translation].
Liedberg et al. (2003). “Sentinel-Node-Diagnostik Beim Invasiven (Bladder Cancer and the Sentinel Node Concept),” Aktuel Urol. 34:115-118, (English Abstract Only).
Liedberg, F. et al. (Jan. 2006). “Intraoperative Sentinel Node Detection Improves Nodal Staging in Invasive Bladder Cancer,” The Journal of Urology 175(1):84-89.
Lippincott's New Medical Dictionary. “Perfusion,” p. 707 (1897), three pages.
Liptay, M.J. (Mar. 2004). “Sentinel Node Mapping in Lung Cancer,” Annals of Surgical Oncology 11(Supplement 3):271S-274S.
Little, J.R. et al. (May 1979). “Superficial Temporal Artery to Middle Cerebral Artery Anastomosis: Intraoperative Evaluation by Fluorescein Angiography and Xenon- 133 Clearance,” Journal of Neurosurgery 50(5):560-569. [Exhibit 1002].
Liu Q. P. et al. (Apr. 2007). “Bacterial Glycosidases for the Production of Universal Red Blood Cells” Nature Biotechnology 25(7):454-464.
Lund, F. et al. (Nov. 1997). “Video Fluorescein Imaging of the Skin: Description of an Overviewing Technique for Functional Evaluation of Regional Cutaneous Blood Evaluation of Regional Cutaneous Perfusion in Occlusive Arterial Disease of the Limbs,” Clinical Physiology 17(6):619-633.
Mack, M.J. et al. (Sep. 1998). “Arterial Graft Patency in Coronary Artery Bypass Grafting: What Do We Really Know?,” Ann. Thorac. Surg. 66(3):1055-1059.
Magnani, M. et al. (1998). “Erythrocyte Engineering for Drug Delivery and Targeting,” Biotechnol. Appl. Biochem. 28:1-6.
Magnani, M. et al. (Jul. 15, 1992). “Targeting Antiretroviral Nucleoside Analogues in Phosphorylated Form to Macrophasges: In Vitro and In Vivo Studies,” Proc. Natl. Acad. Sci. USA 89(14):6477-6481.
Malmstrom et al. (Nov. 2002). “Early Metastatic Progression of Bladder Carcinoma: Molecular Profile of Primary Tumor and Sentinel Lymph Node,” The Journal of Urology 168(5):2240-2244.
Malmström, P.U. et al. (Jul. 2004). “Re: Extended Radical Lymphadenectomy in Patients With Urothelial Bladder Cancer: Results of a Prospective Multicenter Study,” J. of Urol. 172(1):386, one page.
Marangos, N. et al. (Dec. 2001). “In Vivo Visualization of the Cochlear Nerve and Nuclei with Fluorescent Axonal Tracers,” Hearing Research 162(1-2):48-52.
Martinez-Pérez, M. et al. (Sep. 19, 1996). “Unsupervised Segmentation Based on Robust Estimation and Cooccurrence Data,” Proceedings of the International Conference on Miage Processing (ICIP) Lausanne 3:943-945.
May, S. (May/Jun. 1995). “Photonic Approaches to Burn Diagnostics,” Biophotonics International pp. 44-50.
McKee, T.D. et al. (Mar. 1, 2006). “Degradation of Fibrillar Collagen in a Human Melanoma Xenograft Improves the Efficacy of an Oncolytic Herpes Simplex Virus Vector,” Cancer Research 66(5):2509-2513.
Merriam Webster Medline Plus Medical Dictionary. “Perfusion,” located at http://www.merriam-webster.com/medlineplus/perfusion, last visited on Apr. 15, 2015, one page.
Minciacchi, D. et al. (Jul. 1991). “A Procedure for the Simultaneous Visualization of Two Anterograde and Different Retrograde Fluorescent Tracers—Application to the Study of the Afferent-Efferent Organization of Thalamic Anterior Intralaminar Nuclei” Journal of Neuroscience Methods 38(2-3):183-191.
Mitaka USA, Inc. (2015). “PDE Breast Free Flap Evaluation,” located at <http://mitakausa.com/category/pde_education/flaps/>, last visited on Dec. 29, 2015, four pages.
Mitaka USA, Inc. (2015). “PDE-Neo” located at <http://mitakausa.com/pde-neo/>, last visited on Dec. 29, 2015, two pages.
Mohr, F.W. et al. (May 1997). “Thermal Coronary Angiography: A Method for Assessing Graft Patency and Coronary Anatomy in Coronary Bypass Surgery,” Ann Thorac. Surgery 63(5):1506-1507.
Montán, S. et al. (Feb. 1, 1985). “Multicolor Imaging and Contrast Enhancement in Cancer-Tumor Localization Using Laser-Induced Fluorescence in Hematoporphyrin-Derivative-Bearing Tissue,” Optics Letters 10(2):56-58.
Mothes, H. et al. (Nov. 2004). “Indocyanine-Green Fluorescence Video Angiography Used Clinically to Evaluate Tissue Perfusion in Microsurgery,” The Journal of Trauma Injury, Infection, and Critical Care 57(5):1018-24.
Motomura et al. (1999). “Sentinel Node Biopsy Guided by Indocyanine Green Dye in Breast Cancer Patients,” Japan J. Clin. Oncol. 29(12):604-607.
Mullooly, V.M. et al. (1990). “Dihematoporphyrin Ether-Induced Photosensitivity in Laryngeal Papilloma Patients,” Lasers in Surgery and Medicine 10(4):349-356.
Murphy (2001). “Digital CCD Microscopy,” Chapter 14 in Fundamentals of Light Microscopy And Electronic Imaging, John Wiley and Sons, pp. i-xi and 259-281.
Nahlieli, O. et al. (Mar. 2001). “Intravital Staining with Methylene Blue as an Aid to Facial Nerve Identification in Parotid Gland Surgery” J. Oral Maxillofac. Surgery 59(3):355-356.
Nakamura, T. et al. (1964). “Use of Novel Dyes, Coomassie Blue and Indocyanine Green in Dye Dilution Method,” Tohoka University, Nakamura Internal Department, The Tuberculosis Prevention Society, Tuberculosis Research Laboratory, 17(2):1361-1366.
Nakayama, A. et al. (Oct. 2002). “Functional Near-Infrared Fluorescence Imaging for Cardiac Surgery and Targeted Gene Therapy,” Molecular Imaging 1(4):365-377.
Naumann, T. et al. (Nov. 15, 2000). “Retrograde Tracing with Fluoro-Gold: Different Methods of Tracer Detection at the Ultrastructural Level and Neurodegenerative Changes of Back-Filled Neurons in Long-Term Studies,” Journal of Neuroscience Methods 103(1):11-21.
Newman et al. (Oct. 31, 2008). “Update on the Application of Laser-Assisted Indocyanine Green Fluorescent Dye Angiography in Microsurgical Breast Reconstruction,” American Society of Plastic Surgeons, Plastic Surgery 2008, 2 pages.
Nimura, H. et al. (May 2004, e-published on Mar. 22, 2004). “Infrared Ray Electronic Endoscopy Combined with Indocyanine Green Injection for Detection of Sentinel Nodes of Patients with Gastric Cancer,” British Journal of Surgery 91(5):575-579.
Novadaq Technologies Inc. (Jan. 29, 2007). “Novadaq Imaging System Receives FDA Clearance for use During Plastic Reconstructive Surgery,” PR Newswire three pages.
Novadaq Technologies Inc. (Jan. 19, 2005). 510(k) Summary—Showing X-Ray Fluoroscopy as Predicate Device, Fluorescent Angiographic System, six pages, [Exhibit 1012].
Oddi, A. et al. (Jun. 1996). “Intraoperative Biliary Tree Imaging with Cholyl-Lysyl-Fluorescein: An Experimental Study in the Rabbit” Surgical Laparoscopy & Endoscopy 6(3):198-200.
Ogata, F. et al. (Jun. 2007). “Novel Lymphography Using Indocyanine Green Dye for Near-Infrared Fluorescence Labeling,” Annals of Plastic Surgery 58(6):652-655.
Ohnishi, S. et al. (Jul.-Sep. 2005). “Organic Alternatives to Quantum Dots for Intraoperative Near-Infrared Fluorescent Lymph Node Mapping” Molecular Imaging 4(3):172-181.
Ooyama, M. (Oct. 12-15, 1994). The 8th Congress of International YAG Laser Symposium, The 15th Annual Meeting of Japan Society for Laser Medicine, Sun Royal Hotel, Japan.
Ott, P. (1998). “Hepatic Elimination of Indocyanine Green with Special Reference to Distribution Kinetics and the Influence of Plasma Protein Binding,” Pharmacology & Toxicology 83(Supp. II):5-48.
Oxford Concise Medical Dictionary. “Perfusion,” p. 571 (1980), three pages.
Pagni, S. et al. (Jun. 1997). “Anastomotic Complications in Minimally Invasive Coronary Bypass Grafting,” Ann. Thorac. Surg. 63(6 Suppl):S64-S67.
Palcic et al. (1991). “Lung Imaging Fluorescence Endoscope: A Device for Detection of Occult Lung Cancer,” Medical Design and Material, thirteen pages.
Palcic, B. et al. (1990). “Development of a Lung Imaging Fluorescence Endoscope,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society 12(1):0196-0197.
Palcic, B. et al. (Aug. 1, 1990). “The Importance of Image Quality for Computing Texture Features in Biomedical Specimens,” Proc. SPIE 1205:155-162.
Palcic, B. et al. (Jun. 1, 1991). “Lung Imaging Fluorescence Endoscope: Development and Experimental Prototype,” Proc. SPIE 1448:113-117.
Palcic, B. et al. (Mar. 1991). “Detection and Localization of Early Lung Cancer by Imaging Techniques,” Chest 99(3):742-743.
Pandharlpande, P.V. et al. (Mar. 2005). “Perfusion Imaging of the Liver: Current Challenges and Future Goals,” Radiology 234(3):661-673.
Paques, M. et al. (Mar. 2003). “Axon-Tracing Properties of Indocyanine Green,” Arch Ophthalmol. 121(3):367-370.
Parungo, C.P. et al. (Apr. 2005). “Intraoperative Identification of Esophageal Sentinel Lymph Nodes with Near-Infrared Fluorescence Imaging,” The Journal of Thoracic and Cardiovascular Surgery 129(4):844-850.
Parungo, C.P. et al. (Dec. 2004, e-published on Nov. 15, 2004). “In Vivo Optical Imaging of Pleural Space Drainage to Lymph Nodes of Prognostic Significance,” Annals of Surgical Oncology 11(12):1085-1092.
Peak, M.J. et al. (1986). “DNA-to-Protein Crosslinks and Backbone Breaks Caused by FAR- and NEAR-Ultraviolet and Visible Light Radiations in Mammalian Cells,” in Mechanism of DNA Damage and Repair, Implications for Carcinogenesis and Risk Assessment, SIMIC, M.G. (ed.) et al., Plenum Press, 233 Spring Street, New York, N.Y. 10013, pp. 193-202.
Peiretti et al. (2005). “Human erythrocyte-ghost-mediated choroidal angiography and photocoagulation.” Database Biosis [online] Biosciences Information Service, Philadelphia, PA, US, XP002725023, Database accession No. Prev200600056121 (abstract).
Peiretti, E. et al. (May 2005). “Human Erythrocyte-Ghost-Mediated Choroidal Angiography and Photocoagulation,”Investigative Ophthalmology & Visual Science, ARVO Annual Meeting Abstract 46(13):4282, located at <http://iovs.arvojournals.org/article.aspx?articleid=2403707>, last visited on Oct. 7, 2016, two pages.
Perez, M.T. et al. (Sep. 2002). “In Vivo Studies on Mouse Erythrocytes Linked to Transferrin,” IUBMB Life 54(3):115-121.
Pfister, A.J. et al. (Dec. 1992). “Coronary Artery Bypass Without Cardiopulmonary Bypass,” Ann. Thorac. Surg. 54(6):1085-1092, (Discussion by S.R. Gundry).
Phillips, R.P. et al. (1991). “Quantification of Diabetic Maculopathy by Digital Imaging of the Fundus,” Eye 5(1):130-137.
Piermarocchi, S. et al. (Apr. 2002). “Photodynamic Therapy Increases the Eligibility for Feeder Vessel Treatment of Choroidal Neovascularization Caused by Age-Related Macular Degeneration,” American Journal of Ophthalmology 133(4):572-575.
Profio, A.E. et al. (Jul.-Aug. 1984). “Fluorometer for Endoscopic Diagnosis of Tumors,” Medical Physics 11 (4):516-520.
Profio, A.E. et al. (Jun. 1, 1991). “Endoscopic Fluorescence Detection of Early Lung Cancer,” Proc. SPIE 1426:44-46.
Profio, A.E. et al. (Nov./Dec. 1979). “Laser Fluorescence Bronchoscope for Localization of Occult Lung Tumors,” Medical Physics 6:523-525.
Profio, A.E. et al. (Sep.-Oct. 1986). “Digital Background Subtraction for Fluorescence Imaging,” Medical Physics 13(5):717-721.
Puigdellivol-Sanchez, A. et al. (Apr. 15, 2002). “On the Use of Fast Blue, Fluoro-Gold and Diamidino Yellow for Retrograde Tracing After Peripheral Nerve Injury: Uptake, Fading, Dye Interactions, and Toxicity,” Journal of Neuroscience Methods 115(2):115-127.
Pyner, S. et al. (Nov. 2001). “Tracing Functionally Identified Neurones in a Multisynaptic Pathway in the Hamster and Rat Using Herpes Simplex Virus Expressing Green Fluorescent Protein,” Experimental Physiology 86(6):695-702.
Raabe et al. (2009, e-published on Nov. 12, 2008). “Laser Doppler Imaging for Intraoperative Human Brain Mapping”, NeuroImage 44:1284-1289.
Raabe, A. et al. (Jan. 2003). “Near-Infrared Indocyanine Green Video Angiography: A New Method for Intraoperative Assessment of Vascular Flow,” Neurosurgery 52(1):132-139.
Rava, R.P. et al. (Jun. 1, 1991). “Early Detection of Dysplasia in Colon and Bladder Tissue Using Laser-Induced Fluorescence,” Proc. SPIE 1426:68-78.
Razum, N. et al. (Nov. 1987). “Skin Photosensitivity: Duration and Intensity Following Intravenous Hematoporphyrin Derivatives, HpD and DHE, ” Photochemistry and Photobiology 46(5):925-928.
Report on Observation by C2400-75i and ARGUS20 Under Low illumination conditions, Jan. 17, 2008.
Request for Invalidation mailed on Jun. 29, 2007 for Japanese Patent No. JP-3881550, filed by Hamamatsu Photonics, Inc. (with English Translation).
Reuthebuch, O et al. (Feb. 2004). “Novadaq SPY: Intraoperative Quality Assessment in Off Pump Coronary Artery Bypass Grafting,” Chest 125(2):418-424.
Reuthebuch, O.T. et al. (May 2003). “Graft Occlusion After Deployment of the Symmetry Bypass System,” Ann. Thorac. Surg. 75(5):1626-1629.
Richards-Kortum, R. et al. (Jun. 1991). “Spectroscopic Diagnosis of Colonic Dysplasia: Spectroscopic Analysis,” Biochemistry and Photobiology 53(6):777-786.
Roberts, W.W. et al. (Dec. 1997). “Laparoscopic Infrared Imaging,” Surg. Endoscopy 11(12):1221-1223.
Rodnenkov, O.V. et al. (May 2005). “Erythrocyte Membrane Fluidity and Haemoglobin Haemoporphyrin Conformation: Features Revealed in Patients with Heart Failure,” Pathophysiology 11(4):209-213.
Ropars, C. (ed.) et al. (1987). Red Blood Cells as Carriers for Drugs. Potential therapeutic Applications, Pergamon Press, Oxford, New York, pp. v-vii, (Table of Contents only).
Ross, G.L. et al. (Dec. 2002). “The Ability of Lymphoscintigraphy to Direct Sentinel Node Biopsy in the Clinically N0 Neck for Patients with Head and Neck Squamous Cell Carcinoma,” The British Journal of Radiology 75(900):950-958.
Ross, G.L. et al. (Jul. 2004, e-published on Jun. 14, 2000). “Sentinel Node Biopsy in Head and Neck Cancer: Preliminary Results of a Multicenter Trial,” Annals of Surgical Oncology 11(7):690-696.
Rossi, L. et al. (2001). “Erthrocyte-Mediated Delivery of Dexamethasone in Patients with Chronic Obstructive Pulmonary Disease,” Biotechnol. Appl. Biochem. 33:85-89.
Rossi, L. et al. (1999). “Heterodimer-Loaded Erthrocytes as Bioreactors for Slow Delivery of the Antiviral Drug Azidothymidine and the Antimycobacterial Drug Ethambutol,” Aids Research and Human Retroviruses 15(4):345-353.
Rossi, L. et al. (2004). “Low Doses of Dexamethasone Constantly Delivered by Autologous Erythrocytes Slow the Progression of Lung Disease in Cystic Fibrosis Patients,” Blood Cells, Molecules, and Diseases 33:57-63.
Rozen, W.M. et al. (Jan. 2008). “Preoperative Imaging for DIEA Perforator Flaps: A Comparative Study of Computed Tomographic Angiography and Doppler Ultrasound,” Plastic and Reconstructive Surgery 121(1):9-16.
Rübben, A. et al. (Mar. 1994). “Infrared Videoangiofluorography of the Skin with Indocyanine Green—Rat Random Cutaneous Flap Model and Results in Man,” Microvascular Research 47(2):240-251.
Rubens, F.D. et al. (2002). “A New and Simplified Method for Coronary and Graft Imaging During CABG,” The Heart Surgery Forum 5(2):141-144.
Sakatani, K. et al. (Nov. 1997). “Noninvasive Optical Imaging of the Subarchnoid Space and Cerebrospinal Fluid Pathways Based on Near Infrared Fluorescence,” J. Neurosurg. 87(5):738-745.
Salmon, E.D. et al. (Oct. 1994). “High Resolution Multimode Digital Imaging System for Mitosis Studies In Vivo and In Vitro,” Biol. Bull 187(2):231-232.
Sato, et al., (1991). “Development of a Visualization Method for the Microcirculation of Deep Viscera Using an Infrared Intravital Microscope System,” Research on ME Devices and ME Technology, five pages, (with English Translation).
Satpathy G.R. et al. (Oct. 2004) “Loading Red Blood Cells with Trehalose: A Step Towards Biostabilization,” Cryobiology 49(2):123-136.
Schaff, H.V. et al. (Oct. 15, 1996). “Minimal Thoracotomy for Coronary Artery Bypass: Value of Immediate Postprocedure Graft Angiography,” Supplement to Circulation 94(8):I-51, (Abstract No. 0289), two pages.
Schellingerhout, D. et al. (Oct. 2000). “Quantitation of HSV Mass Distribution in a Rodent Brain Tumor Model,” Gene Therapy 7(19):1648-1655.
Schmued, L. et al. (Aug. 27, 1990). “In Vivo Anterograde and Retrograde Axonal Transport of the Fluorescent Rhodamine-Dextran-Amine, Fluoro-Ruby, Within the CNS,” Brain Research 526(1):127-134.
Schmued, L.C. et al. (Oct. 29, 1993). “Intracranial Injection of Fluoro-Gold Results in the Degeneration of Local but not Retrogradely Labeled Neurons,” Brain Research 626(1-2):71-77.
Schneider Jr., H.C. et al. (Jan. 1975). “Fluorescence of Testicle, An Indication of Viability of Spermatic Cord After Torsion,” Urology V(1):133-136.
Seeman, P. (Jan. 1, 1967). “Transient Holes in the Erythrocyte Membrane During Hypotonic Hemolysis and Stable Holes in the Membrane After Lysis by Saponin and Lysolecithin,” Journal of Cell Biology 32(1):55-70.
Sekijima, M. et al. (Sep. 2004). “An Intraoperative Fluorescent Imaging System in Organ Transplantation,” Transplantation Proceedings 36(7):2188-2190.
Serov, A. et al. (Mar. 1, 2002). “Laser Doppler Perfusion Imaging with a Complimentary Metal Oxide Semiconductor Image Sensor,” Optics Letters 27(5):300-302.
Serov, A.N. et al. (Sep. 23, 2003). “Quasi-Parallel Laser Doppler Perfusion Imaging Using a CMOS Image Sensor,” Proc. SPIE 5067:73-84.
Sezgin, M. et al. (Jan. 2004). “Survey Over Image Thresholding Techniques and Quantitative Performance Evaluation,” Journal of Electronic Imaging 13(1):146-165.
Sherif, A. et al. (Sep. 2001). “Lymphatic Mapping and Detection of Sentinel Nodes in Patients with Bladder Cancer,” The Journal of Urology 166(3):812-815.
Sheth, S.A. et al. (Apr. 22, 2004)“Linear and Nonlinear Relationships between Neuronal Activity, Oxygen Metabolism, and Hemodynamic Responses,” Neuron 42(2):347-355.
Shoaib, T. et al. (Jun. 1, 2001). “The Accuracy of Head and Neck Carcinoma Sentinel Lymph Node Biopsy in the Clinically NO Neck,” Cancer 91(11):2077-2083.
Siemers, B.M. et al. (Nov. 2001). “The Acoustic Advantage of Hunting at Low Heights Above Water: Behavioual Experiments on the European ‘Trawling’ Bats Myotis Capaccinii, M Dasycneme and M. Daubentonii,” J. Eperimental Biol. 204(Pt. 22):3843-3854.
Skalidis, E.I. et al. (Nov. 16, 2004). “Regional Coronary Flow and Contractile Reserve in Patients with Idiopathic Dilated Cardiomyopathy,” Journal of the American College of Cardiology 44(10):2027-2032.
Slakter, J.S. et al. (Jun. 1995). “Indocyanine-Green Angiography,” Current Opinion in Ophthalmology 6(III):25-32.
Smith, G.A. et al. (Mar. 13, 2001). “Herpesviruses Use Bidirectional Fast-Axonal Transport to Spread in Sensory Neurons,” Proceedings of the National Academy of Sciences of the United States of America 98(6):3466-3470.
Soltesz, E.G. et al. (Jan. 2005). “Intraoperative Sentinel Lymph Node Mapping of the Lung Using Near-Infrared Fluorescent Quantum Dots,” Ann. Thorac. Surg. 79(1):269-277.
Sony Corporation. The Sony U-Matic Videocassette Recorder, VO-9800, ten pages, [Exhibit 1015].
Staurenghi, G. et al. (Dec. 2001).“Combining Photodynamic Therapy and Feeder Vessel Photocoagulation: A Pilot Study,” Seminars in Ophthalmology 16(4):233-236.
Stern, M.D. (Mar. 6, 1975). “In Vivo Evaluation of Microcirculation by Coherent Light Scattering,” Nature 254(5495):56-58.
Still, J. et al. (Mar. 1999). “Evaluation of the Circulation of Reconstructive Flaps Using Laser-Induced Fluorescence of Indocyanine Green,” Ann. Plast. Surg. 42(3):266-274.
Still, J.M. et al. (Jun. 2001). “Diagnosis of Burn Depth Using Laser-Induced Indocyanine Green Fluorescence: A Preliminary Clinical Trial,” Burns 27(4):364-371.
Stoeckli, S.J. et al. (Sep. 2001). “Sentinel Lymph Node Evaluation in Squamous Cell Carcinoma of the Head and Neck,” Otolaryngol Head Neck Surg. 125(3):221-226.
Subramanian, V.A. et al. (Oct. 15, 1995). “Minimally Invasive Coronary Bypass Surgery: A Multi-Center Report of Preliminary Clinical Experience,” Supplement to Circulation 92(8):I-645, (Abstract No. 3093), two pages.
Sugi, K. et al. (Jan. 2003). “Comparison of Three Tracers for Detecting Sentinel Lymph Nodes in Patients with Clinical N0 Lung Cancer,” Lung Cancer 39(1):37-40.
Sugimoto, K. et al. (Jun. 2008, e-published on Mar. 19, 2008). “Simultaneous Tracking of Capsid, Tegument, and Envelope Protein Localization in Living Cells Infected With Triply Fluorescent Herpes Simplex Virus 1,” Journal of Virology 82(11):5198-5211.
Suma, H. et al. (2000). “Coronary Artery Bypass Grafting Without Cardiopulmonary Bypass in 200 Patients,” J. Cardiol. 36(2):85-90, (English Abstract only).
Summary of Invention Submitted to EPO, “Development of Novadaq SPY™ Cardiac Imaging Invention,” five pages, Exhibit 1011].
Taggart, D.P. et al. (Mar. 2003). “Preliminary Experiences with a Novel Intraoperative Fluorescence Imaging Technique to Evaluate the Patency of Bypass Grafts in Total Arterial Revascularization,” Ann Thorac Surg. 75(3):870-873.
Taichman, G.C. et al. (Jun. 1987). “The Use of Cardio-Green for Intraoperative Visualization of the Coronary Circulation: Evaluation of Myocardial Toxicity,” Texas Heart Institute Journal 14(2):133-138.
Takahashi, M. et al. (Sep. 2004). “SPY: An Innovative Intra-Operative Imaging System to Evaluate Graft Patency During Off-Pump Coronary Artery Bypass Grafting,” Interactive Cardio Vascular and Thoracic Surgery 3(3):479-483.
Takayama, T. et al. (Apr. 1992). “Intraoperative Coronary Angiography Using Fluorescein Basic Studies and Clinical Application,” Vascular and Endovascular Surgery 26(3):193-199.
Takayama, T. et al. (Jan. 1991). “Intraoperative Coronary Angiography Using Fluorescein” The Annals of Thoracic Surgery 51(1):140-143. [Exhibit 1013].
Tanaka, E. et al. (Jul. 2009). “Real-time Assessment of Cardiac Perfusion, Coronary Angiography, and Acute Intravascular Thrombi Using Dual-channel Near-infrared Fluorescence Imaging,” The Journal of Thoracic and Cardiovascular Surgery 138(1):133-140.
Tang, G.C. et al. (1989). “Spectroscopic Differences between Human Cancer and Normal Lung and Breast Tissues,” Lasers in Surgery and Medicine 9(3):290-295.
Taylor, K.M. (Apr. 1998). “Brain Damage During Cardiopulmonary Bypass,” Annals of Thoracic Surgery 65(4):S20-S26.
The American Heritage Medical Dictionary. “Perfuse.” p. 401 (2008), three pages.
Thelwall, P.E. et al. (Oct. 2002). “Human Erythrocyte Ghosts: Exploring the Origins of Multiexponential Water Diffusion in a Model Biological Tissue with Magnetic Resonance,” Magnetic Resonance in Medicine 48(4):649-657.
Torok, B. et al. (May 1996). “Simultaneous Digital Indocyanine Green and Fluorescein Angiography,” Klinische Monatsblatter Fur Augenheilkunde 208(5):333-336, (Abstract only), two pages.
Tsutsumi, D. et al. “Moisture Detection of road surface using infrared camera,” Reports of the Hokkaido Industrial Research Institute (No. 297), Issued on Nov. 30, 1998, two pages.
Tubbs, R.S. et al. (Apr. 2005). “Anatomic Landmarks for Nerves of the Neck: A Vade Mecum for Neurosurgeons,” Neurosurgery 56(2 Suppl.):ONS256-ONS260.
Unno, N. et al. (Feb. 2008, e-published on Oct. 26, 2007). “Indocyanine Green Fluorescence Angiography for intraoperative assessment of Blood flow: A Feasibility Study,” Eur J Vasc Endovasc Surg. 35(2):205-207.
Uren, R.F. (Jan. 2004). “Cancer Surgery Joins the Dots,” Nature Biotechnology 22(1):38-39.
Valero-Cabré, A. et al. (Jan. 15, 2001). “Superior Muscle Reinnervation after Autologous Nerve Graft or Poly-L-Lactide-ϵ-Caprolactone (PLC) Tube Implantation in Comparison to Silicone Tube Repair,” Journal of Neuroscience Research 63(2):214-223.
Van Son, J.A.M. et al. (Nov. 1997). “Thermal Coronary Angiography for Intraoperative Testing of Coronary Patency in Congenital Heart Defects,” Ann Thorac Surg. 64(5):1499-1500.
Verbeek, X. et al. (2001). “High-Resolution Functional Imaging With Ultrasound Contrast Agents Based on RF Processing in an In Vivo Kidney Experiment”, Ultrasound in Med. & Biol. 27(2):223-233.
Wachi, A. et al. (Apr. 1995). “Characteristics of Cerebrospinal Fluid Circulation in Infants as Detected With MR Velocity Imaging,” Child's Nerv Syst 11(4):227-230.
Wagnieres, G.A. et al. (Jul. 1, 1990). “Photodetection of Early Cancer by Laser Induced Fluorescence of a Tumor-Selective Dye: Apparatus Design and Realization,” Proc. SPIE 1203:43-52.
Weinbeer, M. et al. (Nov. 25, 2013). “Behavioral Flexibility of the Trawling Long-Legged Bat, Macrophyllum Macrophyllum (Phyllostomidae),” Frontiers in Physiology 4(Article 342):1-11.
What is Perfusion? A Summary of Different Typed of Perfusion. (Sep. 1, 2004). Located at, <http://www.perfusion.com/cgi-bin/absolutenm/templates/articledisplay.asp?articleid=1548#.Vo8Hv02FPGj>, last visited on Jan. 7, 2016, two pages.
Wise, R.G. et al. (Nov. 2005). “Simultaneous Measurement of Blood and Myocardial Velocity in the Rat Heart by Phase Contrast MRI Using Sparse q-Space Sampling” Journal of Magnetic Resonance Imaging 22(5):614-627.
Woitzik, J. et al. (Apr. 2005). “Intraoperative Control of Extracranial-Intracranial Bypass Patency by Near-Infrared Indocyanine Green Videoangiography,” J. Neurosurg. 102(4):692-698.
Wollert, H.G. et al. (Dec. 1989). “Intraoperative Visualization of Coronary Artery Fistula Using Medical Dye,” The Thoracic and Cardiovascular Surg. 46(6):382-383.
Wu, C. et al. (Apr. 15, 2005). “cGMP (Guanosine 3′,5′-Cyclic Monophosphate) Transport Across Human Erythrocyte Membranes,” Biochemical Pharmacology 69(8):1257-1262.
Yada, T. et al. (May 1993). “In Vivo Observation of Subendocardial Microvessels of the Beating Porcine Heart Using a Needle-Probe Videomicroscope with a CCD Camera,”Circulation Research 72(5):939-946.
Yamaguchi, S. et al. (Apr. 2005). “Evaluation of Skin Perfusion After Nipple-Sparing Mastectomy by Indocyanine Green Dye” Journal of Saitama Medical University, Japan, 32(2):45-50, (With English Abstract).
Yoneya, S. et al. (Jun. 1998). “Binding Properties of Indocyanine Green in Human Blood,” IOVS 39(7):1286-1290.
Yoneya, S. et al. (Sep. 1993). “Improved Visualization of the Choroidal Circulation with Indocyanine Green Angiography,” Arch Opthalmol. 111(9):1165-1166.
Young. I.T. et al. (1993). “Depth of Focus in Microscopy,” SCIA '93, Proc. of the 8th Scandinavian Conference on Image Analysis, Tromso, Norway, pp. 493-498, six pages.
Canadian Notice of Allowance dated Jan. 4, 2018, for Canadian Application No. 2,750,760, filed on Jul. 25, 2008, one page.
Canadian Notice of Allowance dated Sep. 27, 2017, for Canadian Application No. 2,811,847, filed on Mar. 20, 2013, one page.
Canadian Office Action dated Feb. 27, 2017 for Canadian Application No. 2,750,760, filed on Jul. 25, 2011, three pages.
Canadian Office Action dated Feb. 13, 2018, for CA Application No. 2,963,450 filed on Apr. 3, 2017, three pages.
Canadian Office Action dated Feb. 28, 2018, for CA Application No. 2,963,987 filed on Mar. 27, 2017, five pages.
Canadian Office Action dated Jan. 19, 2017 for Canadian Application No. 2,914,778 filed on Dec. 8, 2015, four pages.
Canadian Office Action dated Mar. 16, 2016, for CA Application No. 2,750,760 filed on Jan. 23, 2009, five pages.
Canadian Office Action dated Nov. 28, 2017 for Canadian Application No. 2,914,778 filed on Dec. 8, 2015, six pages.
Canadian Office Action dated Oct. 25, 2016 for Canadian Patent Application No. 2,811,847, filed on Sep. 20, 2011, three pages.
Canadian Office Action dated Sep. 30, 2015, for CA Application No. 2,811,847, filed on Sep. 20, 2011, four pages.
Chinese Fifth Office Action dated Dec. 19, 2017 for Chinese Application No. 201180057244.8 filed on Sep. 20, 2011, eleven pages.
Chinese First Office Action dated Apr. 6, 2017 for Chinese Application No. 201510214021.8, filed on May 14, 2009, fifteen pages.
Chinese Fourth Office Action dated Mar. 13, 2017 for Chinese Application No. 201180057244.8 filed on Sep. 20, 2011, twenty pages.
Chinese Office Action dated Jul. 3, 2012, issued in counterpart Chinese Application No. 200980123414.0.
Chinese Office Action dated May 23, 2013, issued in counterpart Chinese Application No. 200980123414.0.
Chinese Office Action dated Nov. 12, 2015, for Chinese Patent Application No. 201180057244.8, filed on Sep. 20, 2010, five pages.
Chinese Second Office Action dated Feb. 8, 2018 for Chinese Application No. 201510214021.8, filed on May 14, 2009, seventeen pages.
Chinese Third Office Action dated Aug. 8, 2016 for Chinese Application No. 201180057244.8 filed on Sep. 20, 2011, eighteen pages.
EP Communication in pursuant to Article 94(3) EPC dated Mar. 9, 2016 for European Patent Application No. 09739980.2 filed May 1, 2009, five pages.
European Communication Pursuant to Article 94(3) EPC dated Aug. 31, 2017, for EP Application No. 09739980.2 filed on Nov. 30, 2010, four pages.
European Communication pursuant to Article 94(3) dated May 27, 2016 for EP Application No. 15160177.0 filed on Aug. 11, 2000, five pages.
European Communication Pursuant to Article 94(3) dated Sep. 21, 2017, for European Application No. 16163909.1 filed on Apr. 5, 2016, three pages.
European Communication pursuant to Rules 70(2) and 70a(2) EPC in EP Application No. 09732993.2 dated May 15, 2014.
European Communication pursuant to Rules 70(2) and 70a(2) EPC in EP Application No. 16163909.1, dated Nov. 14, 2016, two pages.
European Communication Under Rule 71(3) EPC (Intention to Grant) dated Dec. 1, 2017, for European patent Application No. 09739980.2, filed on Nov. 30, 2010, seven pages.
European Communication under Rule 71(3) EPC (Intention to Grant) dated Nov. 21, 2017, for European Patent Application No. 15160177.0, filed on Aug. 11, 2000, seven pages.
European Decision in Opposition Proceeding Revoking (Jun. 10, 2010). European Patent No. 1 143 852, thirty pages.
European Decision of European Patent Office Technical Board of Appeal Revoking Counterpart Patent No. 1143852, dated Oct. 23, 2013. [Exhibit-1009].
European Decision to Grant dated Apr. 21, 2017 for EP Application No. 09732993.2, filed on Nov. 8, 2010, two pages.
European Notice of Allowance dated Oct. 21, 2015, for EP Application No. 11 826 475.3, filed on Sep. 20, 2010, eight pages.
European Notice of Allowance dated Oct. 29, 2015, for EP Application No. 09 704 642.9, filed on Jan. 25, 2008, two pages.
European Office Action dated Mar. 27, 2015, for EP Application No. 09 732 993.2, filed on Apr. 14, 2008, six pages.
European Opposition of European Patent No. EP1143852 lodged by Hamamatsu Photonics, Inc., Jul. 30, 2008.
European Summons to attend Oral Proceedings pursuant to Rule 115(1) EPC issued on Apr. 25, 2016, for European patent application No. 09732993.2, filed on Apr. 14, 2009, 5 pages.
European Summons to attend Oral Proceedings pursuant to Rule 115(1) EPC mailed on Dec. 16, 2016, for European patent application No. 15160177.0, filed on Aug. 11, 2000, seven pages.
Extended European Search Report dated Oct. 14, 2015 for EP Application No. 13806313.6 filed on Jun. 20, 2013, nine pages.
Extended European Search Report dated Apr. 28, 2014, for EP Application No. 09 732 993.2, filed on Apr. 14, 2008, eight pages.
Extended European Search Report dated Feb. 22, 2012, for EP Application No. 09 704 642.9, filed on Jan. 25, 2008, fifteen pages.
Extended European Search Report dated Jan. 28, 2014, for EP Application No. 11 826 475.3, filed on Sep. 20, 2010, six pages.
Extended European Search report dated Sep. 16, 2016 for EP Application No. 16183434.6 filed on Aug. 9, 2016, ten pages.
Indian Examination Report dated Jan. 16, 2018 for Indian Application No. 2993/DELNP/2011, filed on Apr. 25, 2011, eleven pages.
Indian Examination Report dated Jul. 28, 2017 for Indian Application No. 1983/MUMNP/2007, filed on Nov. 27, 2007, seven pages.
Indian Examination Report dated Sep. 22, 2016 for Indian Application No. 7566/DELNP/2010, filed on Oct. 27, 2010, nine pages.
International Preliminary Examination Report completed on Jul. 1, 2001 for PCT/US00/22088, filed on Aug. 11, 2000, three pages.
International Preliminary Report on Patentability dated Apr. 4, 2017, for PCT Application No. PCT/CA2015/050973 filed on Sep. 28, 2015, six pages.
International Search Report and the Written Opinion of the International Searching Authority, or the Declaration dated Apr. 3, 2008 for PCT/US07/77892, filed on Sep. 7, 2007, ten pages.
International Search Report and Written Opinion dated Jul. 29, 2009 for PCT/US2009/043975 filed on May 14, 2009, eleven pages.
International Search Report and Written Opinion dated Oct. 24, 2017 for PCT Application No. PCT/CA2017/050564 filed on May 10, 2017, fourteen pages.
International Search Report for Application No. PCT/EP2008/008547, dated Jun. 2, 2009; five pages.
International Search Report dated Dec. 3, 2015 for PCT Application No. PCT/CA2015/050973 filed on Sep. 28, 2015, three pages.
International Search report dated Jul. 4, 2008 for International Application No. PCT/US2007/080847, filed on Oct. 9, 2007, three pages.
International Search Report dated Dec. 3, 2009, for PCT Patent Application No. PCT/IB2009/005700, filed on Apr. 14, 2009, three pages.
International Search Report dated Feb. 1, 2012, for PCT Patent Application No. PCT/IB2011/002381, filed on Sep. 20, 2011, five pages.
International Search Report dated Jan. 22, 2014, for PCT Application No. PCT/IB2013/001934, filed on Jun. 20, 2013, four pages.
International Search Report dated Jun. 8, 2009, for PCT Patent Application No. PCT/CA2009/000073, filed on Jan. 23, 2009, three pages.
International Search Report dated Oct. 18, 2000, for PCT Application No. PCT/US2000/22088, filed on Aug. 11, 2000, one page.
International Search Report dated Sep. 11, 2009 for Application No. PCT/US2009/042606 filed on May 1, 2009, five pages.
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 4, 2017, for PCT/CA2017/050564, filed on May 10, 2017, two pages.
Japanese Final Office Action dated Feb. 5, 2018 for Japanese Patent Application No. 2016-014503, filed on Jan. 28, 2016, six pages.
Japanese First Office Action dated Feb. 1, 2016 for Japanese Patent Application No. 2015-517876 filed Jun. 20, 2013, eight pages.
Japanese First Office Action dated Jul. 28, 2017 for Japanese Patent Application No. 2016-203798 filed Oct. 17, 2016, four pages, (with English Translation).
Japanese Notice of Allowance dated Sep. 25, 2017 for Japanese Patent Application No. 2013-529729, filed on Mar. 21, 2013, six pages.
Japanese Notice of Allowance dated Sep. 16, 2016, for Japanese Patient Application No. 2015-517876 filed on Jun. 20, 2013, six pages.
Japanese Office Action dated Apr. 1, 2016, for Japanese Patent Application No. 2013-529729, filed on Mar. 21, 2013, seven pages.
Japanese Office Action dated Jul. 30, 2013, issued in counterpart Japanese Application No. 2011-504574, filed Apr. 14, 2009, six pages.
Japanese Office Action dated Mar. 3, 2017, for Japanese Patent Application No. 2016-014503, filed on Jan. 28, 2016, ten pages.
Japanese Office Action dated Mar. 31, 2017 for Japanese Patent Application No. 2013-529729, filed on Mar. 21, 2013, eleven pages.
Japanese Office Action dated Sep. 14, 2015, for Japanese Patent Application No. 2011-504574, filed on Apr. 14, 2009, three pages.
Japanese Office Action dated Mar. 19, 2018 for Japanese Application No. 2017-518785 filed on Apr. 7, 2017, eight pages.
Korean Notice of Allowance dated Apr. 27, 2017, for Korean Patent Application No. 10-2016-7007994, filed on Mar. 25, 2016, three pages.
Korean Notice of Allowance dated Apr. 29, 2016, for Korean Patent Application No. 10-2010-7024977, filed on Apr. 14, 2009, three pages.
Korean Office Action dated Nov. 30, 2015, for Korean Patent Application No. 10-2010-7024977, filed on Apr. 14, 2009, two pages.
Korean Patent Office, Office Action dated Jun. 25, 2014 in Korean Patent Application No. 10-2013-7035027, filed on May 14, 2009, fifteen pages.
Mexican Office Action dated May 30, 2013, issued in counterpart Mexican Application No. MX/a/2010/011249.
Novadaq Technologies Inc.'s Preliminary Response filed on Aug. 23, 2017 to Petition for Inter Partes Review of U.S. Pat. No. 8,892, sixty one pages.
Partial European Search Report dated Dec. 16, 2010 for European Application No. 10186218.3 filed on Aug. 11, 2000, seven pages.
Partial European Search Report dated Jun. 11, 2014 for European Application No. 13178642.8, filed on May 1, 2009, five pages.
Partial European Search Report dated Jun. 28, 2016 for European Application No. 16163909.1 filed on Apr. 5, 2016, six pages.
Petition for Inter Partes Review of U.S. Pat. No. 8,892, (May 11, 2017), filed by Visionsense Corp., fifty four pages.
Russian Decision on Grant dated Jul. 29, 2013, issued in counterpart Russian Application No. 2011111078.14, five pages.
Russian Office Action dated Mar. 29, 2013, issued in counterpart Russian Application No. 2011111078.14, three pages.
Supplemental European Search Report dated Jul. 6, 2004 for EP Application No. 00955472.6 filed on Aug. 11, 2000, five pages.
Translation of Decision of Japanese Patent Office Trial Board revoking Counterpart U.S. Pat. No. 3,881,550, twenty six pages, [Exhibit 1010].
U.S. Final Office Action dated Apr. 10, 2008, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, six pages.
U.S. Final Office Action dated Apr. 12, 2017, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, nine pages.
U.S. Final Office Action dated Apr. 2, 2013, for U.S. Appl. No. 13/419,368, filed Mar. 13, 2012, five pages.
U.S. Final Office Action dated Apr. 20, 2016, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, seven pages.
U.S. Final Office Action dated Apr. 27, 2011 for U.S. Appl. No. 11/515,419, filed Sep. 1, 2006, nine pages.
U.S. Final Office Action dated Apr. 4, 2017, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, twelve pages.
U.S. Final Office Action dated Aug. 10, 2012, for U.S. Appl. No. 11/912,877, filed Aug. 13, 2008, ten pages.
U.S. Final Office Action dated Dec. 31, 2015 for U.S. Appl. No. 14/177,050, filed Feb. 10, 2014, eighteen pages.
U.S. Final Office Action dated Dec. 4, 2014, for U.S. Appl. No. 12/776,835, filed May 10, 2010, thirteen pages.
U.S. Final Office Action dated Feb. 1, 2013, for U.S. Appl. No. 12/776,835, filed May 10, 2010, thirteen pages.
U.S. Final Office Action dated Feb. 13, 2015, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, six pages.
U.S. Final Office Action dated Feb. 18, 2010, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, six pages.
U.S. Final Office Action dated Feb. 4, 2015 for U.S. Appl. No. 13/314,418, filed Dec. 8, 2011, six pages.
U.S. Final Office Action dated Jul. 21, 2016 for U.S. Appl. No. 14/543,356, filed Nov. 17, 2014, seven pages.
U.S. Final Office Action dated Jul. 9, 2015, for U.S. Appl. No. 14/543,356, filed Nov. 17, 2014, eight pages.
U.S. Final Office Action dated Jun. 1, 2015, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, nine pages.
U.S. Final Office Action dated Jun. 13, 2014, for U.S. Appl. No. 12/776,835, filed May 10, 2010, thirteen pages.
U.S. Final Office Action dated Jun. 25, 2014, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, fifteen pages.
U.S. Final Office Action dated Mar. 20, 2017, for U.S. Appl. No. 14/177,050, filed Feb. 10, 2014, twenty three pages.
U.S. Final Office Action dated Mar. 28, 2013 for U.S. Appl. No. 12/063,349, filed May 12, 2010, twenty pages.
U.S. Final Office Action dated May 29, 2013, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, twelve pages.
U.S. Final Office Action dated Nov. 6, 2013, for U.S. Appl. No. 13/419,368, filed Mar. 13, 2012, five pages.
U.S. Final Office Action dated Oct. 7, 2011 for U.S. Appl. No. 11/851,312, filed Sep. 6, 2007, ten pages.
U.S. Final Office Action dated Sep. 13, 2011, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, five pages.
U.S. Final Office Action dated Sep. 17, 2014 for U.S. Appl. No. 11/515,419, filed Sep. 1, 2006, eleven pages.
U.S. Final Office Action dated Sep. 17, 2015, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, six pages.
U.S. Final Office Action dated Sep. 23, 2004, for U.S. Appl. No. 09/744,034, filed Apr. 27, 2001, seven pages.
U.S. Final Office Action dated Sep. 29, 2016, for U.S. Appl. No. 13/922,996, filed Jun. 20, 2013, fourteen pages.
U.S. Non-Final Office Action dated Apr. 1, 2015, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, fourteen pages.
U.S. Non-Final Office Action dated Apr. 26, 2012, for U.S. Appl. No. 12/776,835, filed May 10, 2010, nine pages.
U.S. Non-Final Office Action dated Apr. 28, 2010, for U.S. Appl. No. 11/946,672, filed Nov. 28, 2007, nine pages.
U.S. Non-Final Office Action dated Aug. 10, 2016 for U.S. Appl. No. 14/177,050, filed Feb. 10, 2014, twenty pages.
U.S. Non-Final Office Action dated Aug. 29, 2014 for U.S. Appl. No. 12/063,349, filed May 12, 2010, nineteen pages.
U.S. Non-Final Office Action dated Dec. 16, 2016, for U.S. Appl. No. 14/868,369, filed Sep. 28, 2015, seven pages.
U.S. Non-Final Office Action dated Dec. 20, 2013, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, thirteen pages.
U.S. Non-Final Office Action dated Dec. 30, 2010, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, six pages.
U.S. Non-Final Office Action dated Feb. 1, 2011 for U.S. Appl. No. 11/851,312, filed Sep. 6, 2007, seven pages.
U.S. Non-Final Office Action dated Feb. 5, 2016, for U.S. Appl. No. 14/543,356, filed Nov. 17, 2014, seven pages.
U.S. Non-Final Office Action dated Jan. 22, 2014 for U.S. Appl. No. 11/851,312, filed Sep. 6, 2007, ten pages.
U.S. Non-Final Office Action dated Jan. 27, 2012, for U.S. Appl. No. 11/912,877, filed Aug. 13, 2008, eleven pages.
U.S. Non-Final Office Action dated Jan. 8, 2018, for U.S. Appl. No. 15/077,677, filed Mar. 22, 2016, nine pages.
U.S. Non-Final Office Action dated Jan. 9, 2009, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, six pages.
U.S. Non-Final Office Action dated Jul. 2, 2015, for U.S. Appl. No. 14/177,050, filed Feb. 10, 2014, nineteen pages.
U.S. Non-Final Office Action dated Jul. 22, 2015 for U.S. Appl. No. 13/314,418, filed Dec. 8, 2011, six pages.
U.S. Non-Final Office Action dated Jul. 8, 2014 for U.S. Appl. No. 13/314,418, filed Dec. 8, 2011, seven pages.
U.S. Non-Final Office Action dated Jun. 11, 2013 for U.S. Appl. No. 11/515,419, filed Sep. 1, 2006, eleven pages.
U.S. Non-Final Office Action dated Jun. 28, 2012 for U.S. Appl. No. 12/063,349, filed May 12, 2010, seventeen pages.
U.S. Non-Final Office Action dated Mar. 10, 2004, for U.S. Appl. No. 09/744,034, filed Apr. 27, 2001, seven pages.
U.S. Non-Final Office Action dated Mar. 13, 2015, for U.S. Appl. No. 14/543,356, filed Nov. 17, 2014, eight pages.
U.S. Non-Final Office Action dated Mar. 22, 2018 for U.S. Appl. No. 15/610,102, filed May 31, 2017, eleven pages.
U.S. Non-Final Office Action dated Mar. 6, 2007, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, eight pages.
U.S. Non-Final Office Action dated May 21, 2015, for U.S. Appl. No. 13/922,996, filed Jun. 20, 2013, fourteen pages.
U.S. Non-Final Office Action dated May 6, 2015 for U.S. Appl. No. 12/063,349, filed May 12, 2010, seventeen pages.
U.S. Non-Final Office Action dated Nov. 18, 2016, for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, six pages.
U.S. Non-Final Office Action dated Nov. 27, 2015, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, six pages.
U.S. Non-Final Office Action dated Nov. 9, 2015, for U.S. Appl. No. 14/177,045, filed Feb. 10, 2014, seven pages.
U.S. Non-Final Office Action dated Oct. 12, 2016, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, nine pages.
U.S. Non-Final Office Action dated Oct. 13, 2017, for U.S. Appl. No. 13/922,996, filed Jun. 20, 2013, seventeen pages.
U.S. Non-Final Office Action dated Oct. 26, 2017, for U.S. Appl. No. 14/543,429, filed Nov. 17, 2014, nine pages.
U.S. Non-Final Office Action dated Oct. 28, 2016, for U.S. Appl. No. 14/543,356, filed Nov. 17, 2014, eight pages.
U.S. Non-Final Office Action dated Oct. 3, 2013, for U.S. Appl. No. 12/776,835, filed May 10, 2010, twelve pages.
U.S. Non-Final Office Action dated Sep. 15, 2010, for U.S. Appl. No. 11/106,154, filed Apr. 14, 2005, six pages.
U.S. Non-Final Office Action dated Sep. 27, 2017 for U.S. Appl. No. 14/177,050, filed Feb. 10, 2014, twenty two pages.
U.S. Non-Final Office Action dated Sep. 30, 2010 for U.S. Appl. No. 11/515,419, filed Sep. 1, 2006, eleven pages.
U.S. Non-Final Office Action dated Sep. 5, 2012 for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, seven pages.
U.S. Notice of Allowance dated Apr. 17, 2014, for U.S. Appl. No. 13/419,368, filed Mar. 13, 2012, five pages.
U.S. Notice of Allowance dated Aug. 7, 2014, for U.S. Appl. No. 13/850,063, filed Mar. 25, 2013, nine pages.
U.S. Notice of Allowance dated Dec. 2, 2016, for U.S. Appl. No. 14/598,832, filed Jan. 16, 2015, seven pages.
U.S. Notice of Allowance dated Dec. 6, 2017, for U.S. Appl. No. 15/476,290, filed Mar. 31, 2017, nine pages.
U.S. Notice of Allowance dated Jul. 12, 2017, for U.S. Appl. No. 14/868,369, filed Sep. 28, 2015, nine pages.
U.S. Notice of Allowance dated Jul. 13, 2016, for U.S. Appl. No. 14/598,832, filed Jan. 16, 2015, seven pages.
U.S. Notice of Allowance dated Mar. 15, 2016, for U.S. Appl. No. 14/598,832, filed Jan. 16, 2015, seven pages.
U.S. Notice of Allowance dated Mar. 29, 2018, for U.S. Appl. No. 14/177,050, filed Feb. 10, 2014, ten pages.
U.S. Notice of Allowance dated Mar. 7, 2005, for U.S. Appl. No. 09/744,034, filed Apr. 27, 2001, five pages.
U.S. Notice of Allowance dated May 26, 2016, for U.S. Appl. No. 14/177,045, filed Feb. 10, 2014, eight pages.
U.S. Notice of Allowance dated Nov. 25, 2015, for U.S. Appl. No. 14/598,832, filed Jan. 16, 2015, seven pages.
U.S. Notice of Allowance dated Nov. 30, 2010, for U.S. Appl. No. 11/946,672, filed Nov. 28, 2007, six pages.
U.S. Notice of Allowance dated Oct. 16, 2014, for U.S. Appl. No. 13/850,063, filed Mar. 25, 2013, eight pages.
U.S. Notice of Allowance dated Oct. 18, 2012, for U.S. Appl. No. 12/841,659, filed Jul. 22, 2010, seven pages.
U.S. Notice of Allowance dated Oct. 4, 2013, for U.S. Appl. No. 11/912,877, filed Aug. 13, 2008, nine pages.
U.S. Notice of Allowance dated Oct. 6, 2014, for U.S. Appl. No. 13/419,368, filed Mar. 13, 2012, five pages.
U.S. Restriction Requirement dated Jun. 26, 2017, for U.S. Appl. No. 15/077,677, filed Mar. 22, 2016, seven pages.
Written Opinion for Application No. PCT/EP2008/008547, dated Jun. 2, 2009; eleven pages.
Written Opinion of the International Searching Authority dated Jul. 4, 2008 for International Application No. PCT/US2007/080847, filed on Oct. 9, 2007, six pages.
Written Opinion of the International Searching Authority dated Dec. 3, 2009, for PCT Patent Application No. PCT/IB2009/005700, filed on Apr. 14, 2009, six pages.
Written Opinion of the International Searching Authority dated Dec. 3, 2015 for PCT Application No. PCT/CA2015/050973 filed on Sep. 28, 2015, five pages.
Written Opinion of the International Searching Authority dated Feb. 1, 2012, for PCT Patent Application No. PCT/IB2011/002381, filed on Sep. 20, 2011, four pages.
Written Opinion of the International Searching Authority dated Jan. 22, 2014, for PCT Application No. PCT/IB2013/001934, filed on Jun. 20, 2013, six pages.
Written Opinion of the International Searching Authority dated Jun. 8, 2009, for PCT Patent Application No. PCT/CA2009/000073, filed on Jan. 23, 2009, four pages.
U.S. Appl. No. 15/591,909, filed May 10, 2017, by Moore et al.
Baumgartner, R. et al. (1987). “Section V—In vivo Localization and Photodynamic Therapy: A Fluorescence Imaging Device for Endoscopic Detection of Early Stage Cancer—Instrumental and Experimental Studies,” Photochemistry and Photobiology 46(5):759-763.
Baumgartner, R. et al. (Jan. 1, 1990). “A Fluorescence Imaging Device for Endoscopic Detection of Early Stage Cancer Instumental and Experimental Studies,” Section Five in SPIE. Press, ed. Abraham Katzir, pp. 513-517, eight pages. Reprinted by Permission by SPIE. Press from Photochemistry and Photobiology 46(5):759-763, (1987).
Canadian Office Action dated Dec. 12, 2018 for CA Application No. 2,963,987 filed on Mar. 27, 2017, four pages.
Canadian Office Action dated Nov. 28, 2018 for CA Application No. 2,750,760 filed on Jan. 23, 2009, three pages.
European Extended Search Report dated Jul. 16, 2018 for EP Application No. 15846111.1, filed on Apr. 25, 2017, thirteen pages.
Korean Office Action dated Dec. 4, 2018 for Korean Patent Application No. 2017-7011565, filed on Apr. 4, 2017, nine pages.
U.S. Notice of Allowance dated Dec. 18, 2018 for U.S. Appl. No. 13/922,996, filed Jun. 20, 2013, six pages.
Australian Notice of Allowance dated Sep. 17, 2018 for Australian Patent Application No. 2015327665, filed on Mar. 23, 2017, three pages.
Australian Office Action dated Jun. 26, 2018 for Australian Patent Application No. 2014408488, filed on Mar. 31, 2017, nine pages.
Brazilian Office Action dated May 14, 2019 for Brazilian Application No. PI 0907272-1, filed on Oct. 14, 2010, five pages.
Canadian Office Action dated Dec. 28, 2018 for CA Application No. 2,963,450 filed on Apr. 3, 2017, four pages.
Canadian Office Action dated May 28, 2019 for Canadian Application No. 3,011,310, filed on Jul. 11, 2018, four pages.
Chinese Office Action dated Apr. 17, 2019 for Chinese Application No. 201510214021.8, filed on May 14, 2009, sixteen pages.
Chinese Office Action dated Apr. 26, 2019 for CN Application No. 201580064648.8 filed on May 26, 2017, twenty six pages.
Chinese Office Action dated Sep. 27, 2018 for Chinese Application No. 201510214021.8, filed on May 14, 2009, seventeen pages.
European Notice of Allowance dated Mar. 15, 2018 for EP Application No. 09739980.2 filed on Nov. 30, 2010, two pages.
European Office Action dated Apr. 6, 2018 for EP Application No. 15188378.2 filed on Oct. 5, 2015, four pages.
European Office Action dated May 28, 2018 for EP Application No. 16183434.6 filed on Aug. 9, 2016, four pages.
European Search Report dated Jan. 10, 2018 for EP Application No. 17171383.7 filed on May 16, 2017, eleven pages.
European Search Report dated Jun. 6, 2018 for EP Application No. 18166591.0 filed on Apr. 10, 2018, six pages.
European Search Report dated May 23, 2018 for EP Application No. 14903635.2 filed on May 2, 2017, nine pages.
European Summons to Attend the Oral Proceedings dated Oct. 24, 2018 for European Application No. 16163909.1 filed on Apr. 5, 2016, four pages.
Japanese Final Office Action dated Jan. 28, 2019 for Japanese Patent Application No. 2016-014503, filed on Jan. 28, 2016, 3 pages.
Japanese Final Office Action dated Sep. 25, 2018 for Japanese Application No. 2017-518785 filed on Apr. 7, 2017, six pages.
Japanese Notice of Allowance dated Jan. 25, 2019 for Japanese Application No. 2017-518785 filed on Apr. 7, 2017, six pages.
Japanese Notice of Allowance dated Jun. 7, 2019 for Japanese Patent Application No. 2017-516925 filed on Mar. 28, 2017, six pages.
Japanese Notice of Allowance dated Jun. 8, 2018 for Japanese Patent Application No. 2016-203798 filed Oct. 17, 2016, six pages.
Japanese Notice of Allowance dated May 10, 2019 for Japanese Patent Application No. 2017-205499, filed on Nov. 24, 2017, six pages.
Japanese Office Action dated Aug. 20, 2018 for Japanese Patent Application No. 2017-205499, filed on Nov. 24, 2017, six pages.
Japanese Office Action dated Nov. 19, 2018 for Japanese Patent Application No. 2017-516925 filed on Mar. 28, 2017, four pages.
Korean Notice of Allowance dated May 20, 2019 for Korean Patent Application No. 2019-7005800, filed on Feb. 26, 2019, three pages.
Korean Notice of Allowance dated Nov. 30, 2018 for Korean Patent Application No. 10-2017-7012463, filed on May 8, 2017, three pages.
Korean Office Action dated Apr. 17, 2018 for Korean Patent Application No. 10-2017-7012463, filed on May 8, 2017, six pages.
Li, X. et al. (May 12, 2004). “Method for Retinal Vessel Detection and Diameter Measurement,” Presented at Medical Imaging 2004: Image Processing, San Diego, CA, Proceedings of SPIE 5370:1746-1754.
Martinez-Perez, M.E. et al. (Aug. 2002). “Retinal Vascular Tree Morphology: A Semi-Automatic Quantification,” IEEE Transactions of Biomedical Engineering 49(8):912-917.
U.S. Notice of Allowance dated Dec. 4, 2018 for U.S. Appl. No. 11/515,419, filed on Sep. 1, 2006, seven pages.
U.S. Notice of Allowance dated Jan. 10, 2019 for U.S. Appl. No. 15/610,102, filed May 31, 2017, five pages.
U.S. Notice of Allowance dated Jun. 15, 2018 for U.S. Appl. No. 11/515,419, filed Sep. 1, 2006, five pages.
U.S. Notice of Allowance dated May 15, 2019 for U.S. Appl. No. 15/610,102, filed May 31, 2017, eight pages.
U.S. Notice of Allowance dated Oct. 17, 2018 for U.S. Appl. No. 12/933,477, filed Sep. 20, 2010, seven pages.
U.S. Notice of Allowance dated Oct. 29, 2018 for U.S. Appl. No. 12/063,349, filed May 12, 2010, eight pages.
U.S. Notice of Allowance dated Sep. 6, 2018 for U.S. Appl. No. 12/776,835, filed May 10, 2010, five pages.
U.S. Notice of Allowance dated Sep. 6, 2018 for U.S. Appl. No. 13/922,996, filed Jun. 20, 2013, nine pages.
U.S. Notice of Allowance dated Sep. 26, 2018 for U.S. Appl. No. 15/610,102, filed May 31, 2017, eight pages.
U.S. Appl. No. 16/291,930, filed Mar. 4, 2019. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office dated Sep. 21, 2004).
U.S. Appl. No. 16/356,766, filed Mar. 18, 2019. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office dated Sep. 21, 2004).
U.S. Restriction Requirement dated Jan. 17, 2019 for U.S. Appl. No. 15/591,909, filed May 10, 2017, seven pages.
Related Publications (1)
Number Date Country
20180120230 A1 May 2018 US
Provisional Applications (1)
Number Date Country
62056830 Sep 2014 US
Continuations (1)
Number Date Country
Parent 14868369 Sep 2015 US
Child 15799727 US